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Abstract. Drug repositioning refers to the concept of discov-
ering novel clinical benefits of drugs that are already known 
for use treating other diseases. The advantages of this are that 
several important drug characteristics are already established 
(including efficacy, pharmacokinetics, pharmacodynamics and 
toxicity), making the process of research for a putative drug 
quicker and less costly. Drug repositioning in oncology has 
received extensive focus. The present review summarizes the 
most prominent examples of drug repositioning for the treat-
ment of cancer, taking into consideration their primary use, 
proposed anticancer mechanisms and current development 
status.
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In previous decades, a considerable amount of work has been 
conducted in search of novel oncological therapies; however, 
cancer remains one of the leading causes of death globally. 
The creation of novel drugs requires large volumes of capital, 
alongside extensive experimentation and testing, comprising 
the pioneer identification of identifiable targets and corrobora-
tion, the establishment of the lead compound, and subsequent 
studies into efficacy, pharmacokinetics and toxicity. After this 
arduous process, a minimal number of possible oncology drugs 
reach clinical trials, a fraction that is considered to be ~5% (1). 
Then, if the three phases of clinical trials are successful, 
the new compound can be authorized for use in therapeutic 
settings. The traditional method of developing new anticancer 
drugs is a pervasive, stringent and expensive procedure (1,2). 
Paul et al (3,4) estimated that the time of development of a 
new drug from beginning to end was 11.4‑13.5 years, and 
Adams et al (3,4) analyzed that the costs range between 
161-1,800 million dollars per pharmaceutical product. 
Despite the enormous quantities of money invested in drug 
discovery, the number of novel molecules introduced into the 
clinic has not increased significantly. An alternative method 
in drug development is the consideration of approved known 
molecules used in non‑oncological situations (5). This strategy 
has previously been termed drug repositioning, drug repur-
posing, drug reprofiling, therapeutic switching or indication 
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switching, of which, drug repositioning is the most frequently 
used. The significant advantage of this strategy is that various 
characteristics of these drugs, such as their pharmacokinetics, 
pharmacodynamics and toxicity, are already well known in 
animals and humans (6). Due to the basis of repurposing, 
new candidates could be ready for clinical trials faster, and if 
successfully approved by regulatory authorities, their integra-
tion into medical practice could be more agile. Repurposed 
drugs are generally approved quicker (3‑12 years) and at a 
reduced cost (50‑60% compared with novel compounds) (7). 
Also, while ~10% of new drug applications gain market 
approval, ~30% of repurposed drugs are approved, giving 
companies a market‑driven incentive to repurpose existing 
assets (8).
Research into repurposing drugs in oncology has been 
growing in the past years (9). One example is the Repurposing 
Drugs in Oncology project, an international collaboration initi-
ated by several researchers, clinicians and patient advocates 
working in the non‑profit sector (10). It is out of the sphere 
of this article to discuss the strategies for identifying repur-
posing opportunities (knowledge mining, in silico approaches, 
high‑throughput screening). For the analysis of those strate-
gies, the review of Xue et al (11) is recommended. At present, 
>270 drugs are being analyzed for potential antitumor activity; 
of these, ~29% are on the World Health Organization Essential 
Medicines List (12). Furthermore, ~75% of these drugs are 
off‑patent, and ~57% exhibited antitumor activity in human 
clinical trials (11). The purpose and significance of this review 
is to summarize updated information concerning the most 
promising drugs for repurposing in oncology, and combining 
analysis of their structures, the tumors that are affected by 
them, their diverse mechanisms of action and novel information 
regarding the clinical trials currently being conducted.
2. Artesunate (ART) 
ART is a semi‑synthetic byproduct of artemisinin, a sesqui-
terpene compound isolated from the plant Artemisia annua 
used to treat malaria, generally in combination with other 
drugs (13). Malaria is caused by Plasmodium falciparum, 
which mostly resides in red blood cells and contains iron‑rich 
heme‑groups (14). The proposed mechanism of action for 
its treatment involves the cleavage of endoperoxide bridges 
by iron, producing free radicals which damage biological 
macromolecules, causing oxidative stress in the cells of the 
parasite (15). Several published case reports and pilot phase I/II 
trials indicate clinical anticancer activity of this compound in 
a variety of solid tumors, such as Kaposi's sarcoma, non‑small 
cell lung cancer (NSCLC), and colon, melanoma, breast, 
ovarian, prostate and renal cancers (16‑28). Cases of hepa-
totoxicity were found when artemisinin was combined with 
other drugs (29).
The mechanism of action of ART in cancer remains a matter 
of debate. The cellular response of cancer cells to ART may 
be due to toxic free radicals generated by an endoperoxide 
moiety, cell cycle arrest, induction of apoptosis or inhibition 
of tumor angiogenesis (30). Multiple studies revealed that the 
inhibitory effect of ART on cancer cells is iron‑dependent, 
and iron‑triggered ART radicals are more likely to alkylate 
cellular proteins covalently (17,31,32). Thus, Zhou et al (31) 
concluded that three modes could be involved in ART 
alkylation. One of them involves the molecule binding in a 
specific and noncovalent manner, following which a covalent 
bond is formed by heme activation. Additionally, ART may 
non‑specifically bind to the surface of proteins, primarily 
high abundance proteins, with covalent bonds formed 
by heme activation. The last model proposed involves the drug 
alkylating heme‑containing proteins through heme or amino 
acid residues nearby. There is no clear consensus on the topic. 
Currently, five clinical trials are actively recruiting (clinical 
trial nos. NCT02633098, NCT03093129, NCT03792516, 
NCT03100045 and NCT02786589).
3. Auranofin (AUF)
Rheumatoid arthritis is defined by persistent inflammation and 
joint swelling, leading to functional disability (33). AUF is an 
Au(I) complex containing an Au‑S bond that is maintained 
by a triethyl phosphine group (34). AUF is prescribed for 
the treatment of rheumatoid arthritis, as it can slow disease 
progression by inhibiting inflammation and stimulating 
cell‑mediated immunity (35). Also, AUF inhibits phagocytosis 
by macrophages, as well as the release of lysosomal enzymes 
and antibodies involved in cytotoxicity (36). The use of AUF is 
rare today due to the emergence of novel antirheumatic medi-
cations. AUF's anticancer properties were observed in a wide 
range of cancers, such as melanoma, leukemia, gastrointestinal 
stromal tumor (GIST) and NSCLC, among others (37‑39). This 
organogold compound was also used in combination with 
other drugs; for instance, AUF enhanced the toxicity of tumor 
suppressor candidate 2 (TUSC2)/erlotinib synergistically (40). 
In the presence of AUF, several cancer cell lines exhibited 
increased susceptibility to the TUSC2/erlotinib combination, 
undergoing apoptosis.
Furthermore, it was found that those patients with rheu-
matoid arthritis treated with AUF had lower malignancy 
rates than those not treated (41). The antineoplastic antitumor 
effect is attributed mainly to the interaction of AUF with a 
selenocysteine residue within the redox‑active domain of 
mitochondrial thioredoxin reductase, blocking its activity, and 
leading to increases in reactive oxygen species (ROS) levels 
and apoptosis (36). The second primary mechanism is due 
to the inhibition of the ubiquitin‑proteasome pathway. This 
pathway is required for targeted degradation of proteins within 
cells, which is upregulated in various cancers (36). A number 
of the drugs undergoing repositioning affect the PI3K/Akt 
and mTOR signaling pathways, two pathways which are so 
interconnected that they could be regarded as a single pathway 
crucial to numerous aspects of cell growth and survival (42). 
Disruptions in the Akt‑regulated pathways are associated with 
cancer, and Akt has become a valuable therapeutic target (43). 
Li et al (39) proposed that AUF inhibits the PI3K/Akt/mTOR 
axis, inducing potent anticancer activity. Currently, one clinical 
trial is recruiting in order to analyze the combination of AUF 
and Sirulimus in lung cancer (clinical trial no. NCT01737502).
4. Benzimidazole derivatives (BZMs)
BZMs are heterocyclic organic compounds with structural 
analogy to nucleotides. They are used as a significant scaffold 
INTERNATIONAL JOURNAL OF ONCOLOGY  56:  651-684,  2020 653
for the development of a variety of drugs (44,45). BZM‑based 
compounds are broadly used as anthelmintic drugs with low 
mammalian toxicity and high effectivity against a wide range 
of helminth species (46). The mechanism of action of BZMs 
is based on its specific binding to tubulin, resulting in the 
disruption of microtubule structure and function, interfering 
with the microtubule‑mediated transport of secretory vesicles 
in the absorptive tissues of helminths whilst also affecting 
their structure in tumor cells (47). Additionally, BZMs inhibit 
glucose uptake, deplete glycogen stores and decrease the 
formation of ATP, leading to the death of the parasites (48). 
Certain BZM‑based compounds have shown antitumor 
activity. Including albendazole (ABZ), flubendazole (FLU), 
mebendazole (MBZ) and omeprazole (OMP).
ABZ. ABZ is a medication used for the treatment of a variety of 
helminth infestations (49). The antiproliferative effect of ABZ 
has been observed in vitro in hepatocellular carcinoma (HCC) 
and colorectal carcinoma (CRC) cells, as well as in vivo in a 
xenograft model of peritoneal carcinomatosis (50). ABZ was 
also active in cells resistant to other microtubule drugs, such as 
leukemia and ovarian cancer cells (51,52). Its antitumor mecha-
nism of action appears to depend on its ability to interfere with 
microtubules (53). Another mechanism of antitumor action 
has been proposed for ABZ; it inhibited vascular endothelial 
growth factor (VEGF) production and tumor angiogenesis in 
mice bearing peritoneal ovarian tumors (54). Currently, one 
clinical trial is recruiting to investigate ABZ in cancer (clinical 
trial no. NCT02366884).
FLU. FLU is mainly used in veterinary medicine for the treat-
ment of intestinal parasites (55). FLU exhibits antiproliferative 
effects in leukemia, multiple myeloma (MM), melanoma and 
breast cancer cells (56). FLU alters microtubule structure, 
induces apoptosis, inhibits angiogenesis, induces cell differ-
entiation, inhibits cell migration and induces ROS activating 
autophagy (57,58). In a study of a panel of 26 cancer cell lines, 
neuroblastoma was identified as a highly FLU‑sensitive malig-
nancy (59). The antineuroblastoma activity of FLU involved 
the mouse double minute homolog 2 inhibitor and p53 acti-
vator nutlin‑3 (59). In combined regimens, FLU enhanced 
the cytotoxicity of fluorouracil, doxorubicin, vinblastine and 
vincristine (56). At present, no clinical studies into the effects 
of FLU on human malignancies have been conducted (60).
MBZ. MBZ is used to treat several helminths infestations (49). 
Two different glioblastoma multiforme (GBM) animal 
models showed a survival benefit of treatment with MBZ (61). 
Additionally, growth inhibition was found in lung cancer 
cells (62). Growth inhibition involves the prevention of the 
polymerization of tubulin (63). MBZ was found to interact with 
several protein kinases, including inhibiting BCR‑ABL (64). 
Furthermore, MBZ induces apoptosis in melanoma cell lines 
through phosphorylation of Bcl2 and decreased levels of the 
X‑linked inhibitor of apoptosis (65). Treatment with MBZ 
was as effective as temozolomide in a human melanoma 
xenograft model, and displayed strong therapeutic efficacy in 
animal models of both glioma and medulloblastoma, reaching 
therapeutically effective concentrations in the brain (65,66). 
Currently, six actively recruiting clinical trials are ongoing, 
testing MBZ in different types of tumors either as a single 
drug or in combination with other compounds (clinical 
trial nos. NCT03925662, NCT03628079, NCT02644291, 
NCT02366884, NCT03774472, NCT01837862).
OMP. OMP is a widely used medication for peptide ulcers and 
other gastrointestinal diseases, and is a selective proton pump 
inhibitor (PPI) that inhibits acid secretion via specific inhibi-
tion of the H+/K+‑ATPase system found in the parietal cells of 
the stomach. Jin et al (67) found that the OMP inhibits the inva-
sion of breast and pancreatic cancer cells through inhibition of 
chemokine receptor type 4 transcription. Also, it was found 
that when it is given as an adjuvant drug for relieving common 
side effects of chemotherapy, OMP has a synergetic effect in 
improving chemoradiotherapy efficacy and decreasing rectal 
cancer recurrence (68). As preliminary laboratory studies 
have found that PPIs inhibit human fatty acid synthase and 
breast cancer cell survival, currently, a phase II clinical trial is 
actively recruiting (clinical trial no. NCT02595372) (69).
5. Chloroquine (CLQ)
CLQ and hydroxyCLQ (HCLQ) are 4‑aminoquinolines used 
to treat malaria and autoimmune disorders, including lupus, 
rheumatoid arthritis and amebiasis (70,71). CLQ inhibits the 
enzyme heme polymerase, which converts toxic heme into 
non‑toxic hemozoin. Against rheumatoid arthritis, CLQ mainly 
inhibits lymphoproliferation and phospholipase A2 (72,73). It 
also inhibits thiamine uptake (74). A vast body of experimental 
evidence has demonstrated the efficacy of these two drugs 
against a variety of malignant tumors (75). Such robust data 
allow the development of clinical trials for both molecules, 
suggesting that CLQ may be more efficacious than HCLQ (75). 
Although the vast majority of clinical data was found in 
patients with GBM and brain metastases, and in patients with 
BRAF mutations that block vemurafenib sensitivity, good 
results have also been found in clinical trials for sarcoma, MM 
and lung cancer (76‑79). Inhibition of autophagic flux is the 
most studied anticancer effect of CLQ; however, other studies 
reported CLQ‑induced cell death via inhibition of cholesterol 
biosynthesis (80,81). Additionally, these drugs affect Toll‑like 
receptor 9, p53 and CXC chemokine receptor 4‑CXC ligand 
12 pathways in cancer cells (82). In the tumor stroma, CLQ 
was shown to affect the tumor vasculature, cancer‑associated 
fibroblasts and the immunological system (75). Currently, two 
actively recruiting clinical trials are ongoing, testing CLQ in 
GBM in combination with other compounds (clinical trial 
nos. NCT03243461 and NCT02378532).
Mefloquine (MFQ), another member of the quinoline 
family, has shown cytotoxicity and antiproliferative effects 
against several types of cancer cells. MFQ also exhibits 
good in vivo tumor growth inhibition as a single agent and 
effectively synergizes with primary cancer chemotherapeutics 
in arresting tumor growth (83). The mechanism of action of 
MFQ includes the inhibition of autophagy, lysosomal disrup-
tion, inhibition of various signaling pathways and inhibition 
of P‑glycoprotein (P‑gp), a plasma membrane ATP‑binding 
cassette transporter that extrudes cytotoxic drugs (83). 
Currently, there is one active clinical trial studying MFQ in 
GBM (clinical trial no. NCT01430351).
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6. Chlorpromazine (CPZ)
CPZ is an antipsychotic agent clinically used for the control 
of psychosis symptoms (84). CPZ is a phenothiazine, and an 
antagonist of D2 dopamine receptors in cortical and limbic 
areas of the brain, and the chemical trigger zone (85). CPZ 
has antiproliferative activity in primary brain cultures, 
neuroblastomas and glioma cells (86). The antiproliferative 
effect of CPZ is due to cell cycle arrest at the G2/M phase. 
Shin et al (87) demonstrated that CPZ modulates the p21 
promoter, a regulator of cell cycle progression, via the 
activation of the tumor‑suppressor early growth response 
1 independently of p53. CPZ is also able to induce apop-
tosis-independent autophagic cell death through the inhibition 
of cell cycle progression via the Beclin‑1 dependent pathway 
and modulation of the Akt/mTOR pathway (88). The reported 
cytotoxic effects of CPZ were selective to dividing cells, with 
tumor cells more sensitive than non‑tumor cells (89). CPZ can 
cross the blood‑brain barrier and accumulate in the brain, two 
characteristics which make it an attractive adjuvant in human 
gliomas possessing genetic alterations such as p53 mutation or 
PTEN deletion (90). Furthermore, CPZ can circumvent multi-
drug resistance in cancer cells (91). It has also been reported 
that CPZ can promote apoptosis in leukemia and lymphoma 
cells, and enhances the cytotoxic effect of tamoxifen in tamox-
ifen‑resistant human breast cancer cells (92,93). Moreover, it 
has been proposed as an antitumor drug in CRC via the inhibi-
tion of sirtuin‑1 (94). Additionally, CPZ was able to inhibit the 
growth of orthotopic liver tumors and, in combination with the 
antiparasitic agent pentamidine, produce synergistic inhibitory 
effects on tumor growth (93,95,96). 
7. Clomipramine (CMP)
CMP is a tricyclic drug; its mechanism of action is due to 
mixed inhibition of norepinephrine and serotonin uptake, as 
well as acting as an antagonist of certain G‑protein coupled 
receptors (97). It is used in depression and other psychiatric 
disorders (98). Previous studies demonstrated that CMP had a 
selective cytotoxic effect on all tested brain tumors, probably 
as it crosses the blood-brain barrier and is retained in the brain 
for extended periods (99‑102). In vitro treatment of human 
leukemia cell lines with CMP produces apoptosis due to a 
rapid increase in the production of ROS (103). Mechanistically, 
it has been shown that CMP exerts its antineoplastic effect vi 
inhibition of mitochondrial complex III, leading to decreased 
oxygen consumption and subsequent induction of apoptosis 
via caspase activation (104). CMP has also been proven to be 
useful in combination with other drugs, such as imatinib in 
glioma cells, VRP in drug-resistant tumors and dexamethasone 
in astrocytoma (101,105,106). 
8. Desmopressin (dDAVP)
dDAVP is a synthetic version of vasopressin; it is a medication 
used to treat central diabetes insipidus as a replacement for 
endogenous antidiuretic hormone when this molecule is insuf-
ficient or non‑existent (107). dDAVP limits the amount of water 
eliminated in the urine, functioning at the renal collecting 
duct (108). It binds to vasopression receptor 2 (V2R), which 
signals for the translocation of aquaporin channels, causing 
increased water reabsorption from the urine (109). This water 
becomes passively redistributed from the nephron to the 
circulation by way of basolateral membrane channels (110). As 
dDAVP also stimulates the release of von Willebrand factor 
from endothelial cells, by acting on V2R, it is used to treat 
patients with mild‑to‑moderate cases of moderate hemophilia 
A and von Willebrand disease (111). The FDA authorized 
dDAVP for the treatment of bedwetting in 2017 (112).
The presence of vasopressin receptors has been docu-
mented in various human malignancies, including CRC, 
breast and small cell neuroendocrine tumors (NETs) (113). 
Alonso et al (114) proposed the use of dDAVP in surgical 
oncology, reporting that dDAVP was capable of inhibiting 
lung colonization by blood‑borne tumor cells in preclinical 
mouse models of aggressive breast cancer. In a model of 
subcutaneous tumor manipulation and surgical excision, they 
found that tumor manipulation produced dissemination to the 
axillary nodes, increasing the number of metastasis in the 
lungs by up to 6‑fold; perioperative treatment with dDAVP 
decreased regional metastasis. The percentage of lymph node 
involvement in manipulated animals was 12% with dDAVP 
and 87% without treatment (115). Similar outcomes were 
reported for colon cancer (116). Regarding melanoma, an anti-
metastatic effect was also observed in a model overexpressing 
tissue inhibitor of metalloproteinases‑1 (TIMP‑1) (117). 
Additionally, perioperative administration of dDAVP signifi-
cantly prolonged survival in a clinical veterinary trial in dogs 
with locally advanced mammary cancer (118). It has also 
found that Ddavp may impair the aggressiveness of residual 
mammary tumors during chemotherapy (116).
Summarized evidence on mechanisms of action that 
account for the antitumor activity of dDAVP includes direct 
cytostatic effects, stimulation of microenvironmental produc-
tion of angiostatin and endothelial release of von Willebrand 
factor, a key element in resistance to metastasis (119‑121). It 
was suggested that dDAVP disrupts cooperative interactions 
between the tumor and endothelial cells during early metastatic 
progression (120). A phase II dose‑escalation trial in patients 
with breast carcinoma explored the safety and potential utility 
of perioperative administration of dDAVP in humans (clinical 
trial no. NCT01606072) (121). At the highest dose level evalu-
ated (2 µg/kg), dDAVP appeared safe when administered in 
two slow infusions, before and after surgery. Notably, treat-
ment with dDVAP was associated with reduced intraoperative 
bleeding and a rapid postoperative drop in circulating tumor 
cells, as determined via quantitative PCR of cytokeratin‑19 
transcripts. A trial in patients with rectal bleeding due to CRC 
is ongoing (clinical trial no. NCT01623206). Another research 
group reported enhanced efficacy of docetaxel‑based therapy in 
combination with dDAVP for the treatment of castration‑resis-
tant prostate cancer in an orthotopic model (122,123). The 
perioperative period is an attractive window of opportunity to 
reduce the risk of metastatic disease; in this context, dDAVP 
has emerged as a potential surgical adjuvant in oncology (124).
9. Digoxin (DGX)
DGX is a cardiac glycoside with a long history of use in the 
treatment of heart failure and arrhythmia (125). DGX acts 
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by inhibiting the Na+/K+ ATPase; such inhibition produces 
an increase in intracellular sodium levels, and subsequently 
decreased activity of the Na+/Ca2+ exchanger (126). This 
produces an increase in the intracellular calcium concentra-
tion in myocardiocytes, thereby exerting a beneficial effect in 
the hearts of patients with heart failure or arrhythmia (127). 
It was previously reported owed that DGX decreases breast 
cancer recurrence and aggressiveness (128). However, subse-
quent research found evidence that the use of DGX increased 
breast cancer incidence among females in Denmark, which was 
explained by the fact that DGX is a phytoestrogen (129). Taking 
this into account, a large cohort study with long‑term follow‑up 
reported that DGX reduced the incidence of prostate cancer by 
25% in males (130). Also, males who used DGX for >10 years 
presented a ~46% decrease in the incidence of prostate cancer. 
These data led to a phase II clinical trial for recurrent pros-
tate cancer (clinical trial no. NCT01162135) (131). Estrogens 
diminish the levels of androgen, inhibiting prostate cancer (132). 
Another mechanism proposed is the inhibition of 
hypoxia‑inducible factor (HIF)‑1α synthesis and its target 
genes, such as VEGF (133). Additionally, the binding of cardiac 
glycosides to Na+/K+‑ATPase activates proto‑oncogene tyro-
sine‑protein kinase, epidermal growth factor receptor (EGFR) 
and ERK1/2 phosphorylation, leading to an accumulation of 
p21/CIPI, consequently inducing cell cycle arrest in cancer 
cells (134). Frankel et al (135) conducted a phase IB clinical 
trial of DGX + trametinib, reporting good tolerance and high 
rate of disease control in BRAF wild‑type metastatic mela-
noma. Xia et al (136) found that DGX inhibits the growth of 
chordoma, a rare, slow‑growing malignant tumor arising from 
remnants of the fetal notochord, potentially by inducing the 
apoptosis of tumor cells via a mitochondrial pathway involving 
cytochrome c and caspases‑3/8. Currently, 21 clinical trials 
using DGX (either alone or in combination with other drugs) 
are analyzing its antitumor properties in a variety of tumors. 
10. Disulfiram (DSF)
DSF has been used as an alcohol deterrent for >60 years by 
inhibiting the enzyme acetaldehyde dehydrogenase; it func-
tions by breaking down the acetaldehyde generated from 
enzymatic degradation of alcohol, producing an intense 
discomfort to alcohol consumers (137). DSF has received 
particular attention for its antineoplastic effects, both as a 
single agent and in combination (138). Some of the cytotoxic 
effects are due to its binding to divalent cations, interfering 
with copper‑ and zinc‑dependent processes such as angiogen-
esis and apoptosis (139). Furthermore, it was reported that DSF 
suppresses the proteasome and NF-κB pathways, specifically 
suppressing ubiquitin E3 ligase activity (140,141). DSF also 
affects epigenetic pathways.
DSF contains thiol-reactive functional groups; this chem-
istry is effective in blocking the active site of certain enzymes. 
In prostate cancer, DSF can act as a DNA demethylating agent 
via inhibition of DNA methyltransferase 1 (142). Furthermore, 
in primary GBM cells treated with DSF in vitro, the expres-
sion of kinases such as Polo‑like kinase 1 was reduced at both 
the protein and mRNA levels (143). In ovarian cancer cells, 
DSF administration produced apoptosis via copper-dependent 
induction of heat‑shock proteins (144). DSF was reported to 
stabilize a family of inhibitors called IκBs, the main inhibitors 
of NF-κB, which is dysregulated in cancer (140). Stabilization 
of IκB has been found to re‑sensitize gemcitabine‑resistant 
breast and colon cancer to treatment (145). Similarly, DSF 
resensitized treatment‑resistant GBM cell lines (146). 
Skrott et al (147) found that the molecular target of DSF's 
tumor‑suppressive effects was nuclear protein localization 
protein 4 (Npl4), a substrate‑recruiting cofactor of the cell 
division cycle (Cdc)48p‑Npl4p‑ubiquitin fusion degrada-
tion protein 1p segregase, which is essential for the turnover 
of proteins involved in multiple regulatory and stress‑response 
pathways in cells. Cong et al (148) proposed a chemoradia-
tion regimen targeting stem and non-stem pancreatic cancer 
cells with the addition of DSF. Triscott et al (149) stated that 
DSF kills cancer stem cells (CSCs) of a variety of cancer 
types and propose its use in gliomas. Based on these prom-
ising preclinical studies, a randomized phase II clinical study 
compared the effects of cisplatin alone or in combination with 
DSF, but no difference was found between treated and control 
groups (150). Furthermore, a clinical dose‑escalation trial of 
DSF in patients with recurrent prostate cancer did not suggest 
any clinical benefits (151). However, >15 clinical trials are 
underway at present for breast, prostate, pancreatic and liver 
cancers, as well as melanoma and GBM, among other malig-
nant tumors. Currently, seven actively recruiting clinical trials 
are ongoing testing DSF in GBM alone or in combination 
with other compounds, plus studies in breast and pancreatic 
cancers (clinical trial nos. NCT03323346, NCT02671890, 
NCT03950830, NCT03363659, NCT02678975, NCT03151772 
and NCT02715609). 
11. Doxycycline (DXC)
DXC is a broad‑spectrum bacteriostatic antibiotic commonly 
used for the treatment of various bacterial infections (152). 
DXC inhibits translation by binding to the 16S rRNA 
portion of the ribosome, preventing binding of tRNA to the 
30S bacterial ribosomal subunit, which is necessary for the 
delivery of amino acids for protein synthesis. As a result of 
these actions, the initiation of protein synthesis by polyribo-
some formation is blocked (153). This antibiotic has a long 
half‑life and is currently used successfully for the long‑term 
treatment of acne (154). In addition to its antibiotic effects, 
DXC possesses various non‑antimicrobial activities, including 
its ability to inhibit the activities of various matrix metallo-
proteinases (MMPs), as well as its inhibition of MMP gene 
expression (155). MMPs are zinc‑dependent enzymes reported 
to be involved in the initial stages of invasion and metastasis 
of various tumor cells (156). Lamb et al (157) proposed a 
novel method for the treatment of early cancerous lesions and 
advanced metastatic disease by selectively targeting CSCs 
responsible for tumor initiation, maintenance and metastasis. 
DXC is known to inhibit mitochondrial biogenesis (158). The 
authors found a strict dependence on mitochondrial biogenesis 
for the clonal expansion and survival of CSCs (157). Then, 
the authors tested the ability of DXC to inhibit tumor‑sphere 
formation in a broad panel of cancer cell lines derived from 
eight different tumor types (breast, ductal carcinoma, ovarian, 
prostate, lung, pancreatic, melanoma and GBM) and reported 
inhibitory effects of DXC on all of them (157).
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DXC can induce apoptosis in diffuse large B‑cell lymphoma 
cell lines (159). Also, it has been used in human tumor xeno-
grafts and other animal models to reduce tumor burden and 
metastatic cancer cell growth. For example, in pancreatic 
tumor xenografts, DXC treatment reduced tumor growth by 
~80% (160). In a model of breast cancer bone metastasis, DXC 
reduced bone and bone‑associated soft tissue tumor mass by 
~60 and ~80%, respectively (161). Wan et al (162) showed that 
DXC, in combination with acetylsalicylic acid (AAS), lysine 
and mifepristone, can prevent and treat cancer metastasis. 
Qin et al (163) reported that DXC suppressed the proliferation 
and metastasis of lung cancer cells.
Regarding the mechanism of action of DXC in tumor 
reduction, one of the strongest DXC targets identified 
via quantitative proteomic analysis was DNA‑dependent 
protein kinase (DNA‑PKcs), which is required for proper 
non-homologous end-joining DNA in the maintenance of 
mitochondrial DNA integrity and copy number repair (164). 
DXC confers resistance to radiosensitivity in tumor‑initiating 
cells (165). DNA‑PKcs directly interacts with lymphoid 
enhancer‑binding factor 1, which acts downstream in WNT 
signaling (166). Alexander‑Savino et al (167) analysed the 
gene expression profiles of compounds targeting NF‑κB, and 
discovered that DXC is an inhibitor of the NF‑κB pathway in 
a dose‑dependent manner. DXC inhibits tumor necrosis factor 
(TNF)‑induced NF‑κB activation and reduces the expres-
sion of NF-κB-dependent antiapoptotic proteins, including 
Bcl2α (167). DXC induces cell death through the activation 
of caspase‑8 and release of cytochrome C, suggesting the 
involvement of both extracellular and intracellular path-
ways in apoptosis; through the inhibition of NF‑κB, DXC 
increased ROS in CTCL cells and triggered apoptosis that 
could be reversed through treatment with antioxidants (167). 
At present, >40 clinical trials are ongoing, of which six 
trials are actively recruiting, testing the effects of DXC on 
lymphoma, breast, uterine and lung cancer, as well as in 
malignant pleural effusions (clinical trial nos. NCT02874430, 
NCT02201381, NCT01411202, NCT03465774, NCT02583282 
and NCT02341209). 
12. Fenofibrate (FNF)
FNF, a peroxisome proliferator-activated receptor α (PPAR-α) 
agonist, has been used for decades to treat hypertriglyceridemia 
and mixed dyslipidemia (168). Multiple studies showed that it 
may exhibit antitumor effects in B‑cell lymphoma, prostate 
cancer, GBM, mantle cell lymphoma, squamous cell carcinoma, 
HCC, glioma, melanoma, fibrosarcoma, medulloblastoma, and 
lung, breast and endometrial cancers (169‑171). However, its 
antitumor mechanisms remain unclear. Li et al (169) described 
the induction of apoptosis in triple negative breast cancer 
(TNBC) cells via activation of the NF‑κB pathway in a 
PPAR-α‑independent manner. Cytoprotective pathways, such 
as Akt1 and Erk1/2, may also be involved in the antitumor 
effects of FNF; inhibition of Akt and Erk1/2 pathways led to 
apoptosis and cell cycle arrest. 
One hypothesis in oral cancer suggests targeting 
mitochondrial metabolism to trigger cell death through 
decreasing energy production from the Warburg effect (172). 
Jan et al (173) demonstrated that FNF delayed oral tumor 
development via the reprogramming of metabolic processes. 
FNF induced cytotoxicity by decreasing oxygen consumption 
rates, increasing extracellular acidification rates and reducing 
ATP content (173). Moreover, FNF caused changes in the 
protein expressions of hexokinase II pyruvate kinase, pyru-
vate dehydrogenase, and voltage‑dependent anion channels 
(VDACs), all associated with the Warburg effect (174‑176). 
Furthermore, FNF reprogrammed metabolic pathways by 
interrupting the binding of hexokinase II to VDAC. FBF 
administration suppressed the incidence rate of tongue 
lesions, reduced tumor sizes, decreased tumor multiplicity, 
and reduced the immunoreactivities of VDAC and mTOR. 
The molecular mechanisms involved in the capacity of FNF 
to retard tumor growth included downregulation of mTOR 
via tuberous sclerosis protein (TSC)1/2‑dependent signaling 
through activation of AMPK and suppression of Akt, or via 
a TSC1/2‑independent pathway through direct suppression of 
raptor (173). Currently, four actively recruiting clinical trials 
are ongoing, testing FNF in medulloblastoma, and breast and 
lung cancers (clinical trial nos. NCT01356290, NCT03631706, 
NCT02751710 and NCT03390686).
13. HIV protease inhibitors (HPIs)
HPIs mimic endogenous peptides and inhibit the active site 
of HIV aspartyl protease, a viral enzyme responsible for 
cleaving the Gag‑Pol polyprotein (177). This class of drug 
has been very effective in controlling the effects of HIV in 
patients, and additionally has been shown to possess antitumor 
properties, specially nelfinavir (NLV) and ritonavir (RTV). 
NLV has undergone several preclinical studies in NSCLC, 
MM, liposarcoma, Kaposi's sarcoma, GBM, prostate cancer, 
breast cancer, melanoma and thyroid cancer cells with posi-
tive results (178). Also, a phase II clinical trial of NLV in 
combination with chemoradiation for advanced unresectable 
pancreatic cancer reported acceptable toxicity and prom-
ising survival (179). Another trial using NLV in recurrent 
adenoid cystic cancer of the head and neck showed promising 
results (180). An extensive number of mechanisms under-
lying its antitumor activity have been proposed. First, NLV 
inhibits the PI3K/Akt pathway and cyclin‑dependent kinase 2 
activity via the degradation of Cdc25A phosphatase (181,182). 
Another mechanism involves NLV as an inhibitor of heat 
shock protein 90 (HSP90), suppressing its interaction with 
Akt (183). Also, the induction of endoplasmic reticulum (ER) 
stress and autophagy have been implicated (184). Furthermore, 
NLV was examined as an inhibitor of angiogenesis through 
the downregulation of HIF‑1α (185). Additionally, NLV has 
been reported to exhibit antiviral activity against specific 
HPV‑transformed cervical carcinoma cells, potentially via 
the inhibition of E6-mediated proteasomal degradation of 
mutant p53 (186). There are numerous other possible effects 
that may explain the anticancer effects described, including 
MMP‑9 and MMP‑2 inhibition, increasing radiosensitivity, 
inhibition of NF-κB, blocking of interleukin (IL)‑6, stimu-
lated phosphorylation of signal transducer and activator of 
transcription 3 (STAT3), decreases in ATP levels, androgen 
receptors (ARs) and cell survival, upregulation of TRAIL 
receptor and death receptor 5, Bax upregulation, inhibition 
of EGFR and insulin growth factor receptor 1, and increased 
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fatty acid synthase levels (187‑194). At present, seven clinical 
trials are actively recruiting testing the effects of NLV on 
MM, medulloblastoma, Kaposi's sarcoma, and breast and lung 
cancers (clinical trial nos. NCT02363829, NCT02024009, 
NCT01925378, NCT03256916, NCT03829020, NCT02207439 
and NCT03077451).
Concerning the antitumor activity of RTV, it was 
determined that it reduces proliferation and viability, and 
increases chemosensitivity in MM cell lines (195). Also, it 
was found that RTV has cytostatic and cytotoxic effects on 
GBM cells by inhibiting the chymotrypsin‑like activity of the 
proteasome (196). Another study suggested that RTV, via its 
inhibition of glucose transporter (GLUT)4, decreases glucose 
consumption, lactate production, and the proliferation of 
GBM and MM cells in vitro (195). Also, RTV may interfere 
with HSP90 in GBM cells and exert IL‑18‑inhibiting activi-
ties (197). Ikezoe et al (198) reported that RTV induces growth 
arrest and differentiation of human myeloid leukemia cells, and 
enhances the ability of all‑trans retinoic acid to decrease the 
proliferation and increase the differentiation of these cells. It 
was also found that RTV induced growth arrest and apoptosis 
of human MM via downregulation of the antiapoptotic protein 
myeloid cell leukemia 1 (Mcl‑1) in these cells. Furthermore, 
other studies have shown that RTV blocked IL‑6‑induced acti-
vation of STAT3 and ERK signaling in MM cells by inducing 
growth arrest and apoptosis (198‑200).
Clinically, MM responds to standard drug treatment; 
however, it may acquire drug resistance, subsequently losing its 
responsiveness to previously effective treatments (201). Drug 
resistance may be due to the overexpression of P‑gp. Another 
potential cause of drug resistance involves cytochrome P450 
3A4 (CYP3A4), which is associated with the metabolism of 
chemotherapeutic agents. RTV inhibits P-gp and CYP3A4 
activity (198). Future studies are required to determine 
whether RTV can overcome the drug resistance of MM cells 
in patients. At present, >90% of chronic cases are caused 
by a chromosomal abnormality that produces the so‑called 
Philadelphia chromosome; this aberration is a consequence of 
a fusion between the Abl tyrosine kinase gene at chromosome 
9 and the Bcr gene at chromosome 22, resulting in a chimeric 
oncogene, Bcr-Abl, that is responsible for the production of the 
active Bcr‑Abl tyrosine kinase implicated in the pathogenesis 
of chronic myeloid leukemia (CML) (202). Compounds have 
been developed to inhibit this aberrant tyrosine kinase, such 
as imatinib; however, despite impressive results with imatinib, 
a subset of patients treated with imatinib will develop resis-
tance (203). A total of 6 out of 9 cases of advanced‑stage CML 
with imatinib resistance carried a rare mutation called T315I 
that caused the substitution of threonine for isoleucine at codon 
315 of the Abl protein (204). In 2017, Xu et al (205) virtually 
screened the FDA‑approved drug database to identify novel 
inhibitors for the wild‑type and T315I gatekeeper mutant Abl1, 
finding that RTV could inhibit the T315I mutant Abl1. The only 
clinical trial so far with published results is a phase II trial of 
RTV/lopinavir in cases of progressive or recurrent high-grade 
gliomas that showed no survival benefit (206). However, such 
results must be revisited, as RTV passes poorly through the 
blood‑brain barrier. RTV must be administered with caution in 
patients due to interactions with various drugs (207). Careful 
selection of patients for clinical trials regarding medicine 
consumption is essential. For example, two drugs mentioned 
in this review have negative interactions: DSF decreases the 
metabolism of RTV and statins (STs), increasing the risk of 
rhabdomyolysis (208,209). At present, three clinical trials are 
openly recruiting in breast and prostate cancer (clinical trial 
nos. NCT03890744, NCT04028388 and NCT03066154).
14. Itraconazole (ITZ)
ITZ was developed in 1980 as a triazole antifungal drug (210). 
In contrast to human cells (which present cholesterol in its 
cell membrane), fungi contain ergosterol, a product obtained 
by the demethylation of lanosterol; the mechanism of 
action of ITZ involves the inhibition of CYP450-dependent 
14α‑demethylation of lanosterol, which interferes with the 
fungal ergosterol biosynthesis pathway (211). Its anticancer 
activity was reported for the first time by Chong et al (212), 
who reported that 14α‑demethylase was central for endothe-
lial cell proliferation. Inhibition of WNT/β-catenin signaling 
was observed in basal cells and examined in melanoma 
cells. Additionally, ITZ inhibits VEGF‑ and basic fibroblast 
growth factor (bFGF)‑dependent angiogenesis in vivo (212). 
Concomitantly, ITZ inhibits VEGF receptor 2 (VEGFR2) 
glycosylation, trafficking and signaling in endothelial cells, 
leading to the inhibition of migration and tube formation in 
human vascular endothelial cells (213). Furthermore, in vivo 
experiments demonstrated that ITZ, alone or in combination 
with pemetrexed, exhibits anticancer activity in NSCLC, basal 
cell carcinoma and medulloblastoma (214).
Xu et al (215) demonstrated that ITZ inhibits cholesterol 
trafficking in human endothelial cells, leading to inhibition 
of mTOR. Additionally, Kim et al (216) reported that ITZ 
inhibits the Hedgehog signaling pathway. In GBM cells, 
the decrease of cholesterol in the cell membrane leads to 
decreased Akt1 activity, resulting in inhibition of mTOR and 
subsequent apoptosis (217). Furthermore, the in vivo growth of 
two Hedgehog‑dependent tumor models, a medulloblastoma 
and a basal cell carcinoma, was reduced in animals receiving 
the antifungal drug (216). The same results were obtained in 
another study using pleural mesothelioma cells (218).
Another possible mechanism of action involves the effect of 
ITZ on P‑gp expression (219). Positive results in phase II clinical 
trials for the treatment of lung cancer, prostate cancer and basal 
carcinoma showed good tolerance and type I toxicity (220,221). 
Other studies conducted in breast, lung, ovarian or pancre-
atic cancers also showed promising results (221‑224). More 
clinical trials are currently actively recruiting for different 
types of tumors using ITZ alone or in combination (clinical 
trial no. NCT03513211, NCT02749513, NCT03664115, 
NCT03994211, NCT04018872 and NCT03972748). 
Cautiousness should be exerted, as there is some evidence that 
the use of antifungal drugs may interfere with the actions of 
other anticancer agents, in particular, with rituximab (225).
15. Ivermectin (IVM)
IVM is an antiparasitic drug used to treat numerous types 
of parasitic infestations, belonging to the avermectin family 
of medications. It works by causing the parasite's cell 
membrane to increase its permeability, resulting in paralysis 
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and death. The avermectins are 16‑membered macrocyclic 
lactone derivatives generated as fermentation products by 
Streptomyces avermitilis. IVM has shown some preliminary 
antitumor activity (226‑229). Jiang et al (230) found that IVM 
reversed the resistance of tumor cells to chemotherapeutic 
drugs. Mechanistically, IVM exerts these effects mainly by 
reducing the expression of P-gp via inhibition of the EGFR. 
IVM binds to the extracellular domain of EGFR, inhibiting 
its activation and the downstream ERK/Akt/NF‑κB signaling 
cascade. The inhibition of NF-κB leads to reduced P-gp tran-
scription. IVM also inhibits yes‑associated protein 1 (YAP1), 
which acts by activating the transcription of genes involved 
in cell proliferation and apoptotic suppression (231). An 
exploration of drugs targeting YAP1 showed that IVM has 
antitumor properties (232). Also, IVM exhibits karyopherin 
β1 (KPNB1)‑dependent antitumor properties against ovarian 
cancer (233). KPNB1 encodes nuclear transport factors, and 
in ovarian cancer cells, IVM was found to block KPNB1 
function, causing apoptosis and cell cycle arrest (233). In vivo 
use of IVM with paclitaxel produces a synergistic antitumor 
effect (233). 
IVM was identified as an effective inhibitor of the 
canonical WNT pathway that acts on a transcriptional factor 
of the TCF family, blocking colon and lung cancer prolifera-
tion; such findings were validated in CRC preclinical models 
of tumor growth with cell lines and patient‑derived primary 
tumors (234). Kwon et al (235) found that treatment with IVM 
led to transcriptional modulation of genes associated with the 
epithelial‑mesenchymal transition and maintenance of a CSC 
phenotype in TNBC, resulting in an impairment of clonogenic 
self‑renewal in vitro, and inhibition of tumor growth and 
metastasis in vivo. Beyond the aforementioned examples, IVM 
exerts its antitumor effects in different types of cancer using 
a wide variety of mechanisms. IVM interacts with several 
targets, including the multidrug resistance (MDR) protein, 
the Akt/mTOR pathways, purinergic receptors, p21‑activated 
kinase‑1, cancer‑related epigenetic dysregulators such as 
SIN3A and SIN3B, RNA helicase and chloride channel 
receptors (226).
16. Leflunomide (LFN)
LFN is an inhibitor of the mitochondrial enzyme dihydrooro-
tate dehydrogenase, which plays a central role in the 
de novo pyrimidine synthesis pathway. Therefore, LFN 
inhibits the duplication of rapidly dividing cells, especially 
lymphocytes (236). The FDA approved it as an immuno-
modulatory drug for the treatment of patients with rheumatoid 
arthritis (237). A number of studies reported that LFN inhibits 
the growth of several different cell types, including human 
MM, prostate cancer, NETs, breast cancer and neuroblastoma 
cells (238‑241). Hanson et al (242) showed that LFN exhibits 
potential therapeutic value in treating melanoma. They demon-
strated that LFN reduced cell viability in three melanoma 
cell lines harboring the BRAFV600E mutation. Additionally, 
they found that LFN affects melanoma cells that do not 
harbor BRAF mutations, showing that the treatment of LFN 
with targeted therapies that block components of the propro-
liferative mitogen‑activated protein kinase (MAPK) pathway, 
such as BRAF (inhibited by vemurafenib) and MAPK kinase 
(MEK; inhibited by selumetinib), exhibit synergistic antitumor 
activity in melanoma (242). Caution should be exerted when 
using LFN in combination, since the concomitant use of LFN 
and methotrexate (MTX) could produce lethal liver‑damage or 
hepatotoxicity (243). 
Beyond the aforementioned immunosuppressive effects of 
LFN, other mechanisms of action have been described. For 
example, LFN can induce G1 cell cycle arrest via modulation 
of cyclin D2 and retinoblastoma protein (pRb) expression, 
and decreasing the phosphorylation of Akt, p70 S6 kinas, 
and eukaryotic translation initiation factor 4E‑binding 
protein‑1 (238). As Ephrins and their receptors (Eph) have 
been identified as critical regulators of angiogenesis, Chu and 
Zhang (244) found that LFN has antiangiogenic effects on 
breast cancer cells via the inhibition of the angiogenic soluble 
Ephrin‑A1/EphA2 system. In supernatants of breast cancer 
cell lines co‑cultured with endothelial cells, soluble Ephrin‑A1 
was released from breast cancer cells; the co‑culture superna-
tants containing soluble Ephrin‑A1 caused the internalization 
and downregulation of EphA2 on endothelial cells, and acti-
vation of human umbilical vein endothelial cells (HUVECs). 
The soluble Ephrin‑A1/EphA2 system functions regulating 
angiogenesis in breast cancer, but similar results were found 
in a bladder carcinogenesis model via inhibition of the 
soluble Ephrin‑A1/EphA2 system; Ephrin‑A1 overexpres-
sion could partially reverse LFN‑induced suppression of 
angiogenesis and subsequent tumor growth inhibition (244). 
Cook et al (240) showed that LFN and its natural metabolites 
suppress Achaete-scute homolog 1, both at the protein and 
mRNA level, via a mechanism that is predominately dependent 
upon the Raf‑1/MEK/ERK1/2 pathway. Other mechanisms 
of action have also been considered, as described by Zhang 
and Chu (245). Currently, a phase I/II trial of LFN in females 
with previously treated metastatic TNBC is actively recruiting 
(clinical trial no. NCT03709446).
17. Lithium (LTH)
LTH has traditionally been used for the treatment of bipolar 
disorders (BPD). LTH affects all neurotransmitter pathways 
through highly complex networks. Therefore, it is hypothesized 
to restore the balance among aberrant signaling pathways in 
critical regions of the brain (246). It has been shown that the 
actions of LTH on signal transduction [phosphoinositide hydro-
lysis, adenylyl cyclase, G protein, glycogen synthase kinase 
(GSK)‑3β, protein kinase C and its substrate, myristoylated 
alanine‑rich C kinase substrate] trigger long‑term changes 
in neuronal signaling patterns that account for the protective 
properties of LTH in the treatment of BPD (247,248). Through 
its effects on GSK‑3β and protein kinase C, LTH may also 
modify the level of phosphorylation of cytoskeletal proteins, 
which leads to neuroplastic changes associated with mood 
stabilization (248). Chronic LTH regulates transcriptional 
factors, which in turn may modulate the expression of a variety 
of genes that compensate for aberrant signaling associated 
with the pathophysiology of BPD (248,249). 
LTH effects on cancer cells have been attributed to 
the inhibition of GSK3, which impacts multiple cell func-
tions (250). GSK3 inactivates glycogen synthase, a negative 
regulator of WNT signaling (251). LTH induces anti‑invasive, 
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antimigratory and antiproliferative effects through the inhi-
bition of GSK‑3; knockdown of either GSK‑3α or GSK‑3β 
produced suppression (252). Additionally, LTH changes 
the release of neurotransmitters, modulates the activity 
of several phosphoproteins and directly inhibits inositol 
monophosphatase (253). A study showed inhibitory effects of 
LTH on proliferation and growth in prostate cancer cell lines 
and tumor xenografts via GSK3 inhibition, due to reduced 
interactions between the transcription factor E2F and DNA 
that induce S‑phase gene expression (254). LTH has also been 
shown to increase the effect of doxorubicin and etoposide, 
acting on the cell cycle in prostate cancer cell lines (255). In 
colon cancer cells, it was suggested that LTH could prevent 
metastasis through inhibition of lymphangiogenesis, as the 
inactivation of GSK‑3 downregulates Smad3, which reduced 
expression levels of TGFβ‑induced protein, a key mediator 
of lymphangiogenesis in colon cancer (256). Long‑term use 
of LTH has been associated with nephropathy, and some 
links between LTH and cancer development have been estab-
lished (257). However, this fact remains a matter of debate. In 
a Danish study, overall CRC risk was not affected by the use 
of LTH, although a slight overall risk for distal colon tumors 
was seen (258). LTH is accumulated in GBM cells faster 
and in greater quantities than in neuroblastoma cells, and its 
levels further increase with chronic exposure (259). Other 
studies revealed the anti-invasive potential of LTH in GBM 
cell lines (252,253,259,260). Currently, two actively recruiting 
clinical trials are ongoing, testing LTH in osteosarcoma, CRC 
and esophageal cancer (clinical trial nos. NCT03153280 and 
NCT01669369) (261).
18. Metformin (MET)
MET is a biguanide, widely used for the treatment of type 2 
diabetes. Although MET has been used for >50 years, the 
exact molecular mechanisms of its therapeutic action remain 
a matter of debate (262). MET induces its antihyperglycemic 
effects mainly through the blockage of gluconeogenesis. The 
site of drug action is at the mitochondrial level, mediated 
by transient and specific inhibition of the respiratory‑chain 
complex 1, inducing a drop in cellular energy charge (263). 
As a consequence, cellular ATP concentrations fall, and the 
increase in both ADP/ATP and AMP/ATP ratios triggers 
AMPK. AMPK coordinates a wide array of compensatory, 
protective, and energy‑sparing responses, ultimately leading 
to a reduction in hepatic glucose output (264,265). Additional 
studies are required to understand how MET modulates 
the respiratory‑chain complex 1 (266). Evans et al (267) 
presented evidence that individuals with diabetes treated 
with MET presented a substantially lower cancer burden than 
individuals with diabetes treated with other agents, and other 
studies reached similar conclusions (267‑272). The studied 
populations were patients with type 2 diabetes; therefore, 
its conclusions may not qualify for nondiabetic subjects. 
Additionally, these studies were based on retrospective reviews 
of medical records, and are thus potentially subject to a variety 
of biases (273). Therefore, the utility of MET in oncology is 
based on pharmacoepidemiologic data that are considered 
controversial (274), including studies into prostate cancer risk 
and MM outcomes (275,276). Despite encouraging in vitro 
and epidemiological data for diverse tumor types, available 
results from randomized clinical trials on MET are mostly 
disappointing (277).
The indirect effects of MET on cancer have been described. 
The proposed mechanisms of action of MET in oncology can 
be divided into two broad, non‑mutually exclusive categories: 
Indirect and direct (278). Indirectly, MET acts on the liver to 
inhibit glucose production, producing changes in the meta-
bolic and endocrine circuits that could affect various cellular 
and molecular processes that influence cancer biology. The 
most notable change of oncologic relevance is the reduction of 
hyperinsulinemia, given prior evidence that high insulin levels 
can stimulate the proliferation of a subset of common 
cancers (279). MET also influences adipokine levels in cancer 
biology in vivo, but clinical data are needed (280). Previous 
studies suggested that the immunological or anti‑inflammatory 
modulatory actions of MET are relevant in cancer treatment; 
however, again there are no clinical data to support or refute 
these observations (281,282).
Regarding the direct effects of MET on cancer, dozens of 
in vivo and in vitro studies have reported direct antineoplastic 
activity of MET in model systems without providing relevant 
data for clinical applications (264,278). One study provided 
evidence regarding the role of AMPK; experiments showed 
that activation of AMPK is essential in the action of bigu-
anides by showing that the direct AMPK activator A‑769662 
has antineoplastic activity in vivo (283). Other findings suggest 
the relevance of inhibition of respiratory‑chain complex 
1 (263,284). Modification in the metabolism of cancer cells 
in a manner that is influenced by mutations in exposed cancer 
cells are important consequences of the MET-induced reduc-
tion of oxidative phosphorylation, suggesting that rational drug 
combinations may be a useful approach (285,286). An excellent 
work published by Pollak (278) demonstrated a rationale for 
combining biguanides with inhibitors of kinases that control 
glycolysis. Cancer cells may have a requirement to increase 
oxidative phosphorylation to counterbalance the diminished 
glycolysis that appears as a consequence of oncogenic kinase 
inhibition. With the use of MET, the compensatory increase 
is attenuated, resulting in the enhanced antineoplastic activity 
of the kinase inhibitor (287). Another study found that a 
direct action of MET on cancer cells inhibits growth in vitro 
in association with AMPK activation and inhibition of mTOR, 
as a consequence of MET‑induced energetic stress (288). Other 
mechanisms have also been proposed, showing contradictory 
results; it remains to be determined if AMPK activation in cancer 
cells, due either to the inhibition of oxidative phosphorylation by 
MET or the direct activation by specific pharmacological acti-
vators has antiproliferative or prosurvival consequences (289). 
Cancer cells functionally deficient in AMPK are less likely to 
reduce energy consumption in the face of a biguanide‑induced 
reduction on ATP generation, and are therefore more likely to 
experience a lethal energetic crisis (290). Mutations in genes 
encoding respiratory‑chain complex 1 in cancer cells have 
also been shown to be hypersensitive to biguanides (284,291). 
There are two completed trials on multi‑histology solid tumors 
assessing the dose‑limiting toxicity of various treatments that 
include MET with promising results (292,293). Thus, enthu-
siasm remains for understanding the role of MET in cancer 
through ongoing clinical research (294). At the moment, >80 
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actively recruiting clinical trials are open; details can be found 
in Saraei et al (271). 
19. Niclosamide (NCS)
NCS is a medication used to treat tapeworm infestations by 
inhibiting glucose uptake, oxidative phosphorylation and 
anaerobic metabolism produced in the parasite (295). Mounting 
evidence indicates that NCS is a noteworthy multifunctional 
drug with a wide variety of pharmacological activities, due to its 
capacity to uncouple mitochondrial phosphorylation and modu-
late a selection of signaling pathways associated with tumor 
suppression (296). In adrenocortical carcinoma, it was found 
that NCS inhibits cell proliferation, which was associated with 
apoptosis, reduction of epithelial‑to‑mesenchymal transition, 
β‑catenin levels and mitochondrial uncoupling activity (297).
In breast cancer, Fonseca et al (298) reported that NCS 
inhibits mTOR complex 1 (mTORC1) signaling in a breast 
cancer cell line. A mechanistic study indicated that NCS 
lowers the cytoplasmic pH and may indirectly lead to inhibi-
tion of mTORC1 signaling (299). Wang et al (300) found that 
NCS inhibited the formation of breast cancer spheroids and 
induced apoptosis. Karakas et al (301) reported that NCS 
enhanced the antitumor activity of the palladium(II) sacchari-
nate complex, leading to enhanced cytotoxic activity in breast 
CSCs. In TNBC, it was found that NCS alone or in combina-
tion with cisplatin suppresses the growth of xenografts of 
cisplatin‑resistant cells (302). Mechanistically NCS reversed 
the epithelial‑mesenchymal transition phenotype, inhibited Akt, 
ERK and Src signaling pathways, and inhibited the proliferation 
of both cisplatin‑sensitive and cisplatin‑resistant TNBC (302).
NCS inhibited the growth of colon cancer cells from 
human patients both in vitro and in vivo, regardless of muta-
tions in adenomatous polyposis coli (APC) (303). It was found 
that NCS inhibited colon cell migration, invasion, proliferation 
and colony formation in vitro, and also reduced liver metas-
tasis in a mouse model (304). Suliman et al (305) measured 
growth inhibition and the apoptosis of three colon cancer 
cell lines after treatment with NCS, observing that NCS is 
associated with inhibition of the Notch signaling pathway and 
increased expression of the tumor suppressor microRNA-200 
family. Other studies identified NCS as a selective inhibitor 
of GBM cell viability, revealing that NCS suppressed WNT, 
Notch, mTOR and NF-κB signaling pathways (296,305,306). 
Pre‑exposure to NCS significantly diminished the malignant 
potential of glioma cells in vivo (307). Additionally, it was 
reported that inhibition of STAT3 signaling led to inhibited 
growth of head and neck cancer cells both in vitro and in vivo, 
and enhanced the antitumor effect of erlotinib (308).
The Notch signaling pathway is essential in the generation 
of hematopoietic stem cells, and activated Notch receptors 
are cleaved to release the Notch intracellular domain, which 
moves to the nucleus and binds to transcription factors such 
as CBF1 to alter gene expression (309). NCS was identified as 
an inhibitor of endogenous Notch signaling in acute myeloid 
leukemia (AML) cells (300). Additionally, it was determined 
that NCS increased the levels of ROS in AML cells. NCS 
was synergistic with the chemotherapeutic agents cytarabine, 
etoposide and daunorubicin in vitro, and inhibited the growth 
of AML cells in nude mice (310).
It is estimated that ~20% of patients with NSCLC harbor 
mutations in the EGFR gene, which promotes cancer cell 
growth (311). EGFR inhibitors (such as erlotinib) are used, 
but drug resistance is present in certain cases. It was found 
that NCS treatment overcomes erlotinib resistance, as NCS in 
combination with erlotinib potently suppressed the growth of 
erlotinib-resistant lung cancer cells and increased apoptosis 
in tumors (312). Additionally, NCS is effective in reducing 
the radioresistance of human lung cancers in vitro and 
in vivo; the mechanism involves inhibition of JAK2‑STAT3 
activity induced by radiation (313). One study determined 
that NCS enhanced the suppression of STAT3 in a cell line 
of NSCLC (314). Another study found that NCS reactivated 
the tumor suppressor protein phosphatase 2A in NSCLC 
cells (315). NCS inhibited cell proliferation, colony formation, 
tumor sphere formation and induced mitochondrial dysfunction 
by increasing mitochondrial ROS production (315).
It has been reported that NCS can effectively inhibit 
osteosarcoma cell proliferation, migration, and survival (316). 
This inhibitory effect is associated with decreased expression 
of c‑Fos, c‑Jun, E2F1 and c‑Myc. NCS also inhibits osteosar-
coma tumor growth in a mouse xenograft tumor model (316). 
Additionally, NCS produces growth inhibition of ovarian 
tumor‑initiating cells. Subsequently, NCS was found to inhibit 
ovarian tumor-initiating cells in vitro and in vivo through 
alterations of metabolic pathways in ovarian cancer cells (317). 
King et al (318) found that NCS decreased β-catenin transcrip-
tional activity and reduced cell viability in ovarian carcinoma; 
NCS inhibited tumor growth and the progression of human 
ovarian cancers in xenograft animal models.
Enzalutamide is a novel antiandrogen for the treatment of 
metastatic, castration‑resistant prostate cancer (319). Resistance 
to enzalutamide therapy was reported to be associated with the 
expression of AR splice variants, including the AR-V7 isoform; 
it was found that NCS downregulated AR‑V7 expression and 
inhibited AR‑V7 transcription (320). Treatment of NCS + 
enzalutamide in prostate cancer cells resulted in inhibition of 
colony formation and growth arrest (321). Furthermore, NCS 
was reported to have the ability to inhibit mitochondrial function, 
which is associated with acidic pH in prostate NET cells (322). 
NCS exhibits pH‑dependent toxicity in a castration‑resistant pros-
tate NET cell line (322). Additionally, NCS inhibits proliferation 
and anchorage‑independent colony formation in two renal cell 
carcinoma cell lines, and synergizes with cisplatin and sorafenib 
both in vivo and in vitro (323). Recently, the effects of NCS alone 
and in combination with paclitaxel in cervical cancer were found 
experimentally (324). NCS significantly inhibited proliferation 
and induced apoptosis in a panel of cervical cancer cell lines, 
and inhibited tumor growth in a cervical cancer xenograft 
mouse model, with it demonstrated that NCS induced mito-
chondrial dysfunctions by inhibiting mitochondrial respiration, 
complex I activity and ATP generation, which led to oxidative 
stress (324). Currently, four clinical trials are actively recruiting 
for colon and prostate cancer (clinical trial nos. NCT02687009, 
NCT02687009, NCT03123978 and NCT02807805).
20. Nitroxoline (NTX)
NTX is a widely used antibiotic that is particularly useful 
for the treatment of urinary tract infections. NTX has gained 
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considerable attention due to its anticancer properties. These 
properties have been associated with angiogenesis inhibition 
by targeting methionine aminopeptidase 2 and sirtuin 1/2, 
arresting the migration and invasion of cancer cells by affecting 
cathepsin B, and directly inducing apoptosis (325‑327). 
NTX demonstrated potent anticancer activity against 
various types of cancer cells, including lymphoma, leukemia, 
glioma, and bladder, breast, pancreatic and ovarian cancer cells 
in a dose‑dependent manner (327). Furthermore, NTX effec-
tively and dose‑dependently inhibited the growth of urological 
tumors in orthotopic mouse models (327). Additionally, it was 
found that NTX sulfate, one of the most common metabo-
lites of NTX, may inhibit the proliferation of T24 cells and 
HUVECs (327). The results provide evidence for the repur-
posing of NTX for clinical anticancer applications, particularly 
for bladder cancer treatment (327). These results, in addition to 
the known safety profile of NTX and well‑defined pharmacoki-
netic properties, successfully advanced NTX repurposing into 
a phase II clinical trial in China for non-muscle invasive bladder 
cancer treatment (clinical trial no. CTR20131716) (327). In 
another study, Mao et al (328) found that NTX induced apop-
tosis in >40% MM cells within 24 h, which was induced by 
activation of caspase‑3 and inactivation of poly(ADP‑ribose) 
polymerase, an essential enzyme in DNA damage repair. 
NTX also suppressed prosurvival proteins Bcl‑xL and Mcl‑1. 
Moreover, NTX suppressed the growth of MM xenografts in 
nude mice models. Mechanistically, NTX was found to down-
regulate tripartite motif-containing protein 25 and upregulate 
p53 (328). 
21. Nonsteroidal anti‑inflammatory drugs (NSAIDs)
NSAIDs are a family of drugs used to treat inflammation, 
mild‑to‑moderate pain and fever. Probably the best known 
NSAID is AAS, used since 1897 as an analgesic, antipyretic, 
and inhibitor of platelet aggregation (329). AAS acts as an acet-
ylating agent that covalently attaches an acetyl group to serine 
residue S530 in the active site of cyclooxygenase (COX), leading 
to the inhibition of prostaglandins which are the precursors of 
thromboxanes (330). A substantial body of evidence has estab-
lished that AAS has antineoplastic effects in vitro (331). Those 
studies established a close link between inflammation and 
cancer, suggesting that the anti‑inflammatory properties are the 
central mechanism of action (332). As such, numerous clinical 
trials have been conducted (333). Cole et al (334) performed 
a meta‑analysis of four extensive studies, the Aspirin/Folate 
Polyp Prevention Study, the Colorectal Adenoma Prevention 
Study (Cancer and Leukemia Group B), the United Kingdom 
Colorectal Adenoma Prevention Study and the Association 
pour la Prevention par l'Aspirine du Cancer Colorectal, 
concluding that AAS is an active chemopreventive agent 
in CRC. Additionally, several combinations of AAS with other 
chemopreventive agents have been evaluated for the prevention 
of CRC, in addition to clinical studies investigating the use of 
AAS in treating the dissemination of CRC that leads to liver 
metastases (clinical trial no. NCT03326791) (333).
In patients diagnosed with Lynch syndrome, which leads 
to a higher-than-average chance of developing CRC or endo-
metrial cancer, the anticancer efficacy of AAS was determined 
(clinical trial no. NCT02497820) (333). Additionally, AAS 
may reduce the risk of metastases and death in patients with 
lung, prostate, endometrial and breast cancers (335). Another 
meta‑analysis found a decreasing risk of glioma following 
NSAID treatment, including non-AAS-NSAIDs and AAS; the 
authors concluded that NSAID use was significantly associ-
ated with a lower risk of central nervous system tumors (336). 
Beyond inhibiting the synthesis of prostaglandin E2 (PGE2), 
AAS is associated with increased expression of 15‑hydroxy-
prostaglandin dehydrogenase (15‑HPGD), leading to the 
inactivation of PGE2 by another pathway (337). Furthermore, 
AAS can block PGE2‑induced secretion of the C‑C motif 
chemokine ligand 2 and thus the activation of myeloid‑derived 
suppressor cells, thereby causing immune suppression (338).
Immune function is also influenced by AAS, which 
increases COX‑dependent production of resolvin. Resolvins 
are byproducts of ω‑3 fatty acids, which have an essential role 
in promoting the restoration of normal cell function following 
inflammation (339). As AASs also decrease platelet aggrega-
tion, they could modulate immune function because activated 
platelets suppress the natural killer cell‑mediated lysis of 
tumor cells (340). It was also demonstrated that AAS activates 
the NF-κB signaling pathway, inducing apoptosis in models of 
human cancer (341). At present, >40 clinical trials are actively 
recruiting using AAS alone or in combination to evaluate its 
efficacy in cancer treatment (261).
Beyond AAS, there are other NSAIDs, such as celecoxib 
(CXB), diclofenac (DCF), +‑ibuprofen (IBP), ketorolac 
(KTL), naproxen (NPX), piroxicam (PXM) and sulindac 
(SLD). Various studies have been conducted using NSAIDs 
alone or in combination with other drugs for the treatment of 
cancer (342‑344). It is important to note that NSAIDs reduce 
blood flow to the kidneys, decreasing the elimination of MTX 
and therefore increasing its blood concentration, what could 
increase its side effects (345).
CXB is a selective COX‑2 inhibitor that was approved by 
the FDA for the treatment of familial adenomatous polyposis to 
prevent the formation and growth of colon polyps (261). CXB 
blocks COX‑2 but has little effect on COX‑1, and is therefore 
further classified as a selective COX‑2 inhibitor (346). It was 
found to be useful in the prevention of colon adenomas in a 
randomized clinical trial, but caused potential cardiovascular 
events, which limited its advancement (347). It was reported 
that patients receiving CXB exhibited chemopreventive 
effects. As determined by a decreased cumulative incidence 
of advanced adenomas over 5 years (348). Also, preclinical 
evidence suggests that CXB may provide chemopreventive 
activity against breast cancer. Clinical trials also showed 
positive results; two case‑control studies illustrated that a 
standard dose intake of CXB significantly reduced the risk 
of breast cancer (349,350). CXB inhibits the WNT/β-catenin 
signaling pathway and its gene products, including survivin 
and cyclin D1, exhibiting chemopreventive effects against 
colon cancer (351,352). It is hypothesized that CXB induces 
several potential antitumor mechanisms, including inhibition 
of proliferation, induction of apoptosis, immunoregulation, 
regulation of the tumor microenvironment, antiangiogenic 
effects, and resensitization of other antitumor drugs (353). 
Recently, Yu et al (354) proposed that the effects of CXB 
may be due to regulation of tumor autophagy. Currently, 
23 actively recruiting clinical trials at different stages are 
ARMANDO et al:  DRUG REPOSITIONING IN ONCOLOGY662
studying the safety and effectiveness of CXB in a variety of 
tumor types (355).
Leidgens et al (356) demonstrated that DCF induced c‑myc 
inhibition followed by decreased gene expression of GLUT1, as 
well as decreased lactate dehydrogenase A and lactate secretion, 
leading to decreased lactate-mediated immunosuppression in a 
murine glioma model. Another study from the same research 
group demonstrated that DCF inhibits STAT3 phosphoryla-
tion and lactate formation, induces cell cycle arrest at G2/M, 
and delays tumor growth in an in vivo animal model (356). It 
has also exhibited antitumor activity in a variety of malignant 
cell lines in vitro (357). Arisan et al (358) hypothesized that 
DCF‑mediated apoptosis is associated with inhibition of the 
PI3K/Akt/MAPK signaling axis. DCF also regulates mito-
chondrial adenine nucleotide transferase and the oxidative 
phosphorylation complex V, leading to decoupling of oxida-
tive phosphorylation and subsequent reduced ATP generation 
and cell proliferation (359). In neuroblastoma, DCF enhanced 
chemotherapy‑induced apoptosis via upregulation of p53 (360).
IBP, the most commonly used over‑the‑counter NSAID, 
was efficient at decreasing the mitosis rate and inhibited the 
proliferation of glioma, neuroblastoma, CRC, bladder, breast, 
lung, pancreatic and gastric cancer cells (361,362). In particular, 
this drug showed superior effectiveness compared with other 
NSAIDs in suppressing the proliferation and inducing the 
apoptosis of human prostate cancer cells at clinically relevant 
concentrations (361). In vitro experiments demonstrated that 
IBP induces antiangiogenic effects, apoptosis, reduction of cell 
proliferation, and altered expression of Akt, p53, proliferating 
cell nuclear antigen, Bax and Blc2 (261). 
KTL was proposed to treat oral cancer via inhibition of the 
ATP‑dependent RNA helicase DDX3X (363). Also, KTL salt 
has shown to suppress early breast cancer relapse (364). KTL 
is a chiral molecule administered as a 1:1 racemic mixture of 
the S- and R-enantiomers; the S-enantiomer is considered the 
active component in pain management with selective activity 
against COX enzymes (365). The R‑enantiomer exhibits 
activity as an inhibitor of Rac1 and Cdc42. KTL differs from 
other NSAIDs by functioning as two distinct pharmacologic 
entities due to the independent actions of each enantiomer. In 
a recent review, Hudson et al (365) summarized the evidence 
supporting the benefits of KTL administration for patients 
with ovarian cancer, also discussing how simultaneous inhibi-
tion of these two distinct classes of targets (COX enzymes and 
Rac1/Cdc42 by S‑KTL and R‑KTL, respectively) may each 
contribute to anticancer activity. 
NPX induced significant inhibition of the effects of the 
carcinogen azoxymethane, an inducer of colon adenocarcinoma 
multiplicity in rats (344). Chaudhary et al (366) conducted a 
study using a Ptch1+/−/SKH‑1 hairless mouse model, which is 
highly sensitive to ultraviolet‑B (UVB) radiation; they found 
that NPX also works by reversibly inhibiting both COX‑1 and 
COX‑2. It has been demonstrated that NPX reduces tumors 
developed following chronic UVB irradiation of these animals 
in both basal and squamous cell carcinoma. The mechanism of 
action of NPX remains a matter of debate. A phase I clinical 
study is underway to determine the adverse effects and optimal 
dose of NPX in preventing DNA mismatch‑repair‑deficient 
CRC in patients with Lynch syndrome (clinical trial 
no. NCT02052908) (333). 
PXM blocks ornithine decarboxylase induction, inhibiting 
polyamine production involved in non‑melanoma skin carci-
nogenesis (367). PXM can induce tumor cell apoptosis and 
suppress MMP‑2 activity (368). Actinic keratosis (AK) is a 
chronic progressive disease that may develop into skin cancer; 
damage to the skin is multifactorial, but UVB radiation is the 
paramount factor related to AK pathogenesis (369). Local 
application of PXM inhibits COX, resulting in blockade of the 
biosynthesis of PGs and an increase in 15‑HPGD expression. 
Also, the treatment leads to a reduction of proliferation, tumor 
progression and angiogenesis, as well as an increase in apop-
tosis (370). Campione et al (367,371) found that after topical 
treatment of AK with PXM, typical epidermal architecture 
was restored. The efficacy of PXM is related to its activity 
on both COX enzymes. In a preliminary open‑label trial, 
researchers evaluated the efficacy and tolerability of PXM 1% 
gel in the treatment of patients affected by AKs; they observed 
improvement either in the typical features of the AKs or in 
the perilesional area, observing a healing response in >50% in 
AKs with the use of PXM (367,371). 
Palmerini et al (372) analyzed, in a preclinical model of 
human colon cancer, the action of PXM on cancer progres-
sion in Mlh1+/-/APC1638N/+ mice. PXM diminished the total 
number of tumors per mice by 80% in the small intestine. 
Conversely, PXM augmented tumor incidence, multiplicity 
and volume in the colon. Apoptosis was increased in the 
epithelium of the large intestine; accordingly, tumors 
were decreased at this site. In the cecum, PXM increased 
tumorigenesis, but apoptosis was not diminished, therefore 
suggesting that other mechanisms play a role in the differ-
ential organ‑specific effects of PXM on tumorigenesis (372). 
Further studies are required to elucidate the precise antitumor 
mechanism of action of PXM.
SLD induces apoptosis and inhibits tumor growth in vivo 
in patients with head and neck tumors (373). Additionally, a 
substantial reduction was observed in colonic adenomas in 
patients with familial polyposis (373). Giardiello et al (374) 
reported that SLD decreases the number of adenomas, 
and Takayama et al (375) showed that SLD significantly 
suppresses the number of aberrant crypt foci in a randomized 
trial. Sulindac and its metabolites also appear to induce apop-
tosis in colonic adenomas in vivo (375). One clinical trial is 
actively recruiting to analyze the combination of eflornithine, 
a medication used to treat African trypanosomiasis, and SLD 
in reducing the incidence of adenomas and second primary 
CRCs in patients previously treated for stage 0‑III CRC 
(clinical trial no. NCT01349881).
22. Phosphodiesterase‑5 inhibitors (PDE5Is)
Three PDE5Is, sildenafil (SLD), tadalafil (TLD) and vardenafil 
(VLD), are approved for the treatment of erectile dysfunction 
(ED) (376). SLD and TLD are also approved for the treat-
ment of pulmonary arterial hypertension (377). Additionally, 
there is some evidence of beneficial effects in a variety of 
clinical conditions, including female sexual arousal disorder, 
overactive bladder, incontinence, Raynaud's disease, heart 
failure and stroke (378). Regarding the mechanism of action, 
it should be stressed that the superfamily of mammalian cyclic 
nucleotide PDEs constitute a complex family of hydrolases 
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that catalyze the hydrolytic breakdown of cyclic adenosine 
monophosphate (cAMP) and cyclic guanosine monophos-
phate (cGMP) into their biologically inactive counterparts 
5'‑AMP and 5'‑GMP, respectively (379). Inhibition of the 
breakdown of cGMP, which regulates blood flow in the penis, 
promotes amelioration of the symptoms of ED. Inhibition 
of PDE5 activity is emerging as a promising approach via 
apoptosis and restoration of normal intracellular cGMP levels, 
thereby resulting in the activation of various downstream 
molecules to inhibit proliferation, motility and invasion (380).
There are reports in different tumor cell types of increased 
ROS production and apoptosis following treatment with 
PDE5Is (381). SLD and VLD induced caspase‑dependent 
apoptosis of B‑cell chronic lymphocytic leukemia cells (382). 
Also, PDE5Is were shown to alter the tumor microenviron-
ment by reducing myeloid‑derived suppressor cell function 
and thus augmenting endogenous antitumor immunity (383). 
Enhanced tumor suppression and apoptotic activity were 
seen in a NSCLC cancer orthotopic tumor model following 
SLD‑docetaxel combination treatment (384), as well as with 
a SLD‑capecitabine combination in breast cancer (385) 
and the combination of SLD-doxorubicin in in vivo models 
of prostate cancer (386). High levels of PDE5 have been 
described in several types of cancer, such as prostate, lung and 
breast cancers, CRC and melanoma (387). It was previously 
demonstrated that PDE5/cGMP/protein kinase G signaling 
targets the Hippo/tafazzin pathway to maintain the stemness 
of prostate cancer stem cells, evidencing a new role of PDE5 
in governing stem cell features (388). TLD also attenuated 
TGFβ1‑induced fibroblast‑myofibroblast trans‑differentiation, 
suggesting a potential role for PDE5Is in preventing stromal 
enlargement (389).
A retrospective analysis of 4,974 males showed that 
the prolonged use of PDE5I was associated with a lower 
incidence rate of prostate cancer (390). The apoptotic and 
growth‑inhibitory activities of PDE5Is have been demon-
strated in numerous lung cancer cell lines (391‑393). VLD 
significantly increases the accumulation and enhances the 
antitumor activity of trastuzumab in a xenograft mouse model 
of lung cancer (394). Another study showed that SLD was able 
to enhance the antitumor effects of pemetrexed in NSCLCs, 
and this effect was further enhanced in vivo via co-treatment 
with the mTOR inhibitor temsirolimus (380). Increased PDE5 
expression has been reported in various cell lines deriving 
from breast cancer (395‑397). It was demonstrated that PDE5Is 
could act as chemopreventive agents due to their ability to 
suppress 1‑methyl‑1‑nitrosourea‑induced mammary carcino-
genesis (398). It was reported that SUC metabolites inhibit the 
MEK/ERK signaling cascade in CRC cell lines, indicating 
an additional molecular mechanism via which SUC inhibits 
tumor cell growth (399). Additionally, the treatment of human 
CRC cells with SLD resulted in cell proliferation inhibition, 
cell cycle arrest and apoptosis along with increased intracel-
lular ROS levels in vitro, causing the reduction of xenograft 
tumor growth in nude mice (400).
It has been demonstrated that SLD suppresses polyp 
formation in mice treated with azoxymethane/dextran sulfate 
sodium (401), highlighting the chemopreventive role of PDE5Is. 
In both neuroblastoma and hybrid neuroblastoma‑glioma cells, 
both the presence and regulation of PDE5 mRNA during cell 
differentiation was observed (402). In medulloblastoma cells, 
PDE5Is interacted with vincristine/etoposide/cisplatin to cause 
cell death (403). PDE5I promoted autophagy and enhanced 
chemotherapy‑induced DNA damage in a nitric oxide (NO) 
synthase‑dependent manner (404). Oral administration of 
SLD and VLD selectively improved tumor capillary perme-
ability in gliosarcoma‑bearing rats, without changes in normal 
capillaries (405). Notably, tumor‑bearing rats treated with 
adriamycin in combination with VLD exhibited significantly 
longer survival than rats treated with adriamycin alone (405). 
PDE5I enhanced transport and therapeutic efficacy of trastu-
zumab in hard‑to‑treat brain metastases from different primary 
tumors (406). TLD can also enhance the treatment efficacy of 
the chimeric anti‑CD20 monoclonal antibody rituximab by 
improving the microvascular permeability in an intracranial 
brain lymphoma mice model (407). In thyroid cancer cells 
in vitro, SLD and TLD diminished proliferation, and at lower 
doses, they were also able to reduce cellular migration (408). 
The role of PDE5 in melanoma remains controversial. In 
a cohort study, males who used SLD for ED exhibited a 
significantly elevated risk of developing melanoma (394). 
A case‑control study showed that the use of PDE5Is was 
associated with a modest but significantly increased risk of 
melanoma (409). Later, a large study failed to find evidence of 
a positive association between PDE5I exposure and melanoma 
risk (410). Recently, a meta‑analysis revealed an increased risk 
of malignant melanoma in users of PDE5I (411); however, the 
inherent limitations of observational studies should be consid-
ered. Further studies are needed to evaluate this association 
properly.
23. Pimozide (PMZ)
PMZ is a neuroleptic drug that selectively blocks dopamine 
receptor D2, and is used to treat several mental and mood disor-
ders, such as chronic schizophrenia, as it reduces dopamine 
activity (412). PMZ has been studied as a putative anticancer 
treatment, showing satisfactory results in melanoma, central 
nervous system tumors, osteosarcoma, neuroblastoma, 
myeloproliferative neoplasms, CRC, breast, lung, prostate, 
ovarian and pancreatic cancers, and HCC (412‑423). There 
are several proposed mechanisms of action. PMZ was 
previously shown to inhibit the proliferation of the human 
breast cancer-derived cell line MCF-7 in vitro by blocking 
estradiol‑induced growth (418). Additionally, a previous study 
demonstrated that PMZ is a potential inhibitor of Ran GTPase 
(Ran), which belongs to the Ras superfamily of small GTPases, 
and is involved in various aspects of nuclear structure and 
function, cell cycle regulation, nuclear transport and cell 
transformation (424). By decreasing Ran mRNA expression, 
PMZ also reduces the expression of Akt and phosphorylation 
of VEGFR2 in breast cancer cell lines and HUVECs, leading 
to increased caspase-3 activation and apoptotic cell death. 
PMZ also causes a reduction in cell proliferation, migration 
and invasion in vitro, and lung metastasis in vivo (424). This 
may be due to PMZ‑induced downregulation of MMPs‑1, ‑2 
and ‑14 (413). In myelogenous leukemia cells, PMZ has gained 
attention as an anticancer agent by acting as STAT5 inhibitor, 
as well as an inhibitor of the STAT3 signaling pathway in 
HCC and suppressing cancer stem‑like cell maintenance (413). 
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Also, it has been demonstrated that PMZ inhibited the growth 
of HCC cells by disrupting the WNT/β-catenin signaling 
pathway and reducing epithelial cell adhesion molecule 
expression (422). Furthermore, it has been reported that PMZ 
affects CSCs by inhibiting ubiquitin‑specific protease and WD 
repeat‑containing protein 48, which are proteins responsible 
for inhibiting differentiation and maintaining the cell in an 
undifferentiated state (421). Also, it is of importance to note 
that PMZ induces ROS generation by suppressing catalase 
expression (414). Recently, it has been demonstrated that PMZ 
inhibits P‑gp, increasing apoptosis, as well as the expression of 
pRB and phosphorylated H2AX in KBV20 cells (425). Finally, 
Chen et al (426) reported that PMZ induces a reversible inhibi-
tion of proliferation in liver cancer and has an additive activity 
with sorafenib, which indicates the potential of pimozide as an 
adjuvant anticancer therapy.
24. Propranolol (PPL)
PPL is a competitive antagonist of the cardiac β1-adrenergic 
receptor. It competes with sympathomimetic neurotransmitters 
to bind to receptors, which inhibits sympathetic stimulation of 
the heart. Block of neurotransmitter binding to β1 receptors 
on cardiac myocytes suppress activation of adenylate cyclase, 
inhibiting cAMP synthesis and reducing protein kinase A 
activation (427). This results in less calcium influx to cardiac 
myocytes through voltage‑gated L‑type calcium channels, 
meaning there is a diminished sympathetic action on cardiac 
cells, which produces a decrease in heart rate and arterial blood 
pressure (428). In 2014, PPL was approved by the FDA to treat 
infantile hemangioma (IH), providing improved treatment 
outcomes than previous treatments with corticosteroids, inter-
feron, vincristine or cyclophosphamide (429). IH is a common 
benign tumor of childhood that is potentially disfiguring or 
life‑threatening (430). It is interesting to analyze the mecha-
nism of actions of PPL on IH, as it is an excellent example 
of all the mechanisms of action of PPL working in an inte-
grated form. Early on, PPL causes vasoconstriction through 
the inhibition of NO synthesis and release; ~3 days after the 
beginning of therapy, PPL inhibits the vasodilation mediated 
by adrenalin, leading to vasoconstriction. At ~1 week later, 
PPL induces downregulation of angiogenic factors, such as 
VEGF and bFGF, and promotes remodeling of the extracel-
lular matrix by inhibiting MMP‑2 and MMP‑9, which are vital 
for the process of angiogenesis, producing an abundance of 
TIMPs (155,431). This action, together with the inhibition of 
the proangiogenic ERK/MAPK cascade, causes the inhibition 
of angiogenesis. The long-term effects of PPL are character-
ized by the induction of apoptosis in proliferating endothelial 
cells, producing tumor regression (432).
Based on its therapeutic actions against IH, PPL is 
currently being studied for applications in more malignant 
vascular sarcomas (433). A clinical study found that patients 
treated for >1 year with PPL exhibit a reduced risk of progres-
sion of malignant melanomas and decreased breast cancer 
mortality (434,435). Currently, in vitro studies have found an 
antiproliferative effect of PPL in several types of cancer, such 
as breast, pancreatic and brain cancers (436‑438).
Although PPL is by itself effective in cancer treatment, 
its use in combination with radiotherapy or with standard 
chemotherapy is auspicious. Several malignant tumors have 
limited sensitivity to radiotherapy. In these cases, a radiosensi-
tizer is required to overcome this problem. Several studies have 
shown that antagonists of VEGF, COX‑2 and EGFR expression 
can act as radiosensitizers (439‑441). Rico et al (442) showed 
that PPL reduced cell viability and migration in a panel of 
breast cancer cell lines, and that the effect was increased when 
combined with MET. Furthermore, the combination reduced 
tumor growth in two immunocompetent models of TNBC, 
thereby improving survival. Treatment also reduced metastatic 
growth, with evidence that PPL reduced colonization in the 
lungs. Another group retrospectively assessed the impact of 
selective and non-selective β‑blockers on tumor proliferation 
as measured by Ki67 expression (443). Results showed that 
non-selective β‑blockade reduced tumor proliferation by 66% 
in early‑stage breast cancer. Cell line data showed that PPL 
dose‑dependently reduced tumor cell viability. Data from a 
phase I clinical trial prospectively treated with PPL for 3 weeks 
showed that Ki67 staining was reduced by 23% (clinical trial 
no. NCT00502684) (444).
Endothelial cells are very complex cells expressing a 
variety of molecules and playing an essential role in several 
functions, including vascular permeability, hemodynamic 
sensors endothelium-induced vasodilation, and chemical 
changes (445). Antiangiogenic agents combined with radiation 
therapy increase treatment effectiveness, killing both cancer 
and endothelial cells (446). Regarding chemotherapy, when PPL 
is used in combination with vincristine, its antimitochondrial 
and antimitotic effects in neuroblastoma cells are increased; 
the same results were found in an in vivo study using a neuro-
blastoma mouse model (447). A number of preclinical studies 
combining PPL with chemotherapeutic agents in different 
tumor cell lines have been conducted, including gemcitabine 
in pancreatic cancer cells, imatinib in glioma cells, and PTX in 
TNBC (448). Due to the very advanced stage of the study, it is 
essential to mention the phase III clinical trials combining PPL 
and the COX‑2 inhibitor Etodolac for the prevention of CRC 
recurrence and distant metastatic disease (2). As β‑blockers 
have demonstrated their antitumor properties, it has been 
suggested that α1‑blockers such as terazosin, doxazosin and 
prazosin may also present potential antitumor activity (449). 
At present, >15 clinical trials using PPL are ongoing.
25. Riluzole (RZL)
RLZ is used in the treatment of amyotrophic lateral sclerosis 
by reducing glutamate (GLT) release. RLZ preferentially 
blocks the tetrodotoxin‑sensitive voltage‑gated sodium 
channel (450,451); however, the action of RLZ on GLT recep-
tors has been controversial. The close relationship between 
the cystine/glutamate transporter (xCT) and GLT release has 
been well‑established (452). The xCT system is an amino acid 
antiporter or exchanger that typically mediates the exchange 
of extracellular l‑cystine and intracellular l-GLT across the 
cellular plasma membrane (453).
Aside from its original uses, RLZ has been shown to have 
antitumor effects. The release of GLT in human cancer is well 
established; for instance, glioma cells show a more aggres-
sive phenotype when releasing an excess of GLT, inducing 
neurotoxicity in surrounding neurons (454). Similarly, breast 
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and prostate cancer cells release an excess of GLT, conferring 
on them a growth advantage (455). Additionally, inhibition 
of GLT release by RLZ suppresses the proliferation of GLT 
receptor 1-positive tumor cells in vitro and tumor progression 
in vivo (456). For gliomas and other neuronal cancers, inhibi-
tion of xCT reduces the invasiveness of glioma xenografts, 
likely due to a decrease in GLT release to the extracellular 
space, resulting in reduced excitotoxic death of neurons via 
excess GLT (457). In the prostate, AR drives prostate cancer; 
however, inhibiting AR or androgen biosynthesis induces 
remission for a short time, following which patients acquire a 
more aggressive castration‑resistant condition with reactivated 
AR‑dependent signaling. Downregulating AR expression 
has been considered as a potential treatment for prostate 
cancer (458). Wadosky et al (458) demonstrated that RLZ 
downregulates AR‑full length, mutant ARs and AR‑V7 expres-
sion by protein degradation through the ER stress pathway and 
selective autophagy.
RLZ has also been studied in melanoma. Once trans-
formed, melanoma cells release excess GLT (459). Following 
xCT transport, cystine is reduced into two molecules of 
cysteine (460). In melanocytes, transport of cystine by xCT 
is used for cell growth, glutathione production and protection 
of cells from oxidative stress (453). In the absence of xCT, 
RLZ's GLT release‑inhibitory activity is reduced, producing a 
decrease in RLZ-mediated antiproliferative effects in metabo-
tropic GLT receptor (GRM1)‑expressing tumor cells (457,461). 
In normal melanocytes, the equilibrium between proliferation 
and differentiation is tightly regulated (462). However, in mela-
nomas, released GLT is used either for increasing proliferation 
or promoting antiapoptotic responses resulting from mutations 
in GRM1, 3 and 5, or ionotropic GLT receptors. There is a 
direct and proportional association between xCT levels and 
cell proliferation in vitro/tumor progression in vivo (463). As a 
rapid increase in intracellular GLT induces cell death in PC12 
cells due to an increase of ROS, RLZ-mediated increases 
in intracellular GLT may lead to similar consequences to 
melanoma cells (464). As a response to a rapid increase 
in GLT‑mediated oxidative stress, melanoma cells quickly 
upregulate xCT expression (457). Melanoma cells under 
oxidative stress due to serum starvation promptly upregulate 
xCT protein expression within 2‑3 h. Some melanoma cells 
may survive and acquire resistance to RLZ (465). Therefore, 
these cells can reduce their dependence on xCT, as shown 
in RLZ‑resistant melanoma cell lines (457). Currently, eight 
clinical trials are ongoing for different types of tumors.
26. Statins (STs)
STs are drugs used to treat lipid disorders due to their 
effectiveness in preventing the development of cardiovas-
cular diseases (466). STs inhibit the rate‑limiting enzyme 
3‑hydroxy‑3‑methylglutaryl‑coenzyme A reductase 
(HMG‑CoA) and thus the mevalonate pathway that constitutes 
the initial step in cholesterol biosynthesis (467). Importantly, 
data suggest that inhibition of the HMG‑CoA may underlie 
protective effects against cancer, as the mevalonate pathway 
provides geranylgeranyl pyrophosphate and farnesyl pyro-
phosphate (468). These compounds are used for the prenylation 
of proteins, a process critical for directing these proteins 
to the cell membrane (467,469‑471). Interference with this 
process may be disruptive to cell cycle progression and cell 
proliferation, thereby mediating antineoplastic effects (472).
One study reported the antitumor properties of lovastatin 
(LVS) on F3II sarcomatoid mammary carcinoma, a highly 
invasive and metastatic murine tumor model (473). In female 
mice, treatment increased tumor latency, and decreased 
tumor formation and metastatic dissemination to the lungs. 
The antitumor properties of LVS were strongly associated 
with inhibition of tumor cell attachment and migration; 
these actions were prevented by the presence of mevalonate. 
Incubation of F3II cells with LVS produced a rounded‑cell 
phenotype, lacking cortical actin organization, microtubule 
disruption and inhibition of integrin-mediated focal contacts 
in LVS‑treated cells. LVS decreases membrane localization 
of Rho, a signaling molecule that requires geranylation for 
membrane association and activation (474). Also, LVS induces 
dose‑dependent inhibition of the secretion of urokinase, a key 
proteolytic enzyme during tumor invasion and metastasis, and 
a significant increase of tissue‑type plasminogen activator, a 
marker of good prognosis in mammary cancer (475).
STs affect the small GTPase Rho, which requires 
attachment to cell membranes for proper signaling activity. 
Chimaerins are GTPase‑activating proteins (GAPs) that accel-
erate GTP hydrolysis from Rac, another GTPase of the same 
family (476). F3II cells transfected with the β2-chimaerin 
GAP domain exhibiting low intracellular levels of active 
Rac‑GTP were exposed in vitro to a panel of STs. Transfected 
cells were more sensitive to the cytostatic effects of LVS, 
simvastatin, atorvastatin and rosuvastatin than untransfected 
controls with high Rac‑GTP levels. Transfected tumor cells 
also showed a higher capacity for detachment from the 
substrate and apoptosis after ST exposure (477). STs may 
affect gliomas by altering the mevalonate pathway, with 
subsequent modulations on the RAS‑RAF‑MEK‑ERK or Akt 
signaling pathways (478). Combination treatment of STs with 
azathioprine, a compound that specifically blocks Rac1 activa-
tion, demonstrated an enhanced growth‑inhibitory effect on 
F3II cells (477). Observational studies and meta‑analyses have 
investigated the relationship between cancer incidence and ST 
use (479,480). Studies of all cancer types, as well as specific 
cancers, are inconsistent, although several studies suggest a 
positive association with reduced incidence of gastrointestinal 
cancers. One meta‑analysis, including 7,611 patients with 
gastric cancer in 26 randomized controlled trials and eight 
observational studies, found a 27% risk reduction associ-
ated with ST use (481). Similarly, other meta‑analyses have 
reported that statin use is associated with a reduced risk of 
esophageal cancer, HCC and other prevalent cancer types, 
including breast cancer and CRC (482‑484). However, other 
cohorts and case‑control studies, as well as meta‑analyses, 
have reported only weak or no significant correlation between 
reduced cancer risk and statin use (485,486). In summary, 
studies published up to this point have reported conflicting 
results, and are overall inconclusive. It should be emphasized 
that most clinical trials that have been analyzed have endpoints 
relating to cardiovascular disease. A possible role for STs in 
cancer prevention can only be determined through carefully 
designed clinical trials with a sufficiently long follow‑up and 
cancer incidence as a primary endpoint. At present, ~160 
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clinical trials are evaluating the effect of STs in cancer, both 
as a therapy and as a biomarker regarding the association 
between ST use and cancer incidence. 
27. Thalidomide (THL) 
THL is a classic example of drug repositioning in 
oncology (487). It was developed and commercialized as a 
sedative, and shortly after it was prescribed to mitigate nausea 
and vomiting in pregnancy. It was launched to the market in 
1957, and soon after its popularization, it was observed that 
thousands of newborns presented severe limb defects such 
as amelia and phocomelia. As a consequence, it was banned 
in 1961 (488,489). Currently, it is known that the reason for 
these limb malformations is the binding of THL to cereblon, a 
protein required in normal morphogenesis (490). Such binding 
promotes the recruitment of the DNA‑binding protein Ikaros 
and zinc‑finger protein Aiolos to the E3 complex, leading to 
substrate ubiquitination and degradation (490).
Starting in the 1990s with the research of D'Amato et al (491), 
it was found that THL possesses anticancer properties. 
Subsequently, a clinical trial in patients with MM was carried 
out with positive results, ending in the approval of its use by 
the FDA in combination with dexamethasone in newly diag-
nosed MM patients (492). At present, it is known that THL 
inhibits the production of TNFα, altering the mechanisms of 
intracellular transduction by inhibiting NF‑κB activation and 
the synthesis of IL‑6, affecting cell proliferation, inflamma-
tion, angiogenesis and apoptosis (493). Furthermore, THL 
affects VEGF levels by downregulating its expression (494). 
After FDA approval, new analogs of THL with fewer side 
effects and increased potency were developed and assayed, 
including lenalidomide (LDM), and pomalidomide (PLM), all 
belonging to the class of drugs known as immunomodulatory 
drugs (IMiDs) (495).
In 2003, the FDA granted fast‑track status to LDM for the 
treatment of relapsed or refractory MM. It has been shown that 
LDM has antitumor activity in a variety of types of lymphoma 
and leukemia (496). LDM in combination with dexamethasone 
possesses even higher activity, and the addition of a monoclonal 
antibody appears to improve efficacy even further (497). Then, in 
2015 and 2016, four different combinations of LDM, dexametha-
sone plus a third drug were approved for relapsed/refractory 
MM, with carfilzomib, ixazomib, elotuzumab and daratumumab 
as the third compound (498). Fan et al (499) have described the 
mechanism of action of LDM-the combination of LDM and 
cereblon recruits new substrates (Ikaros, Aiolas and glutamine 
synthetase) that bind to the cereblon‑CRL4 complex, leading to 
increased ubiquitination and proteasome-dependent degradation, 
thus resulting in anti‑MM activity.
PLM was approved in 2013 as a treatment for relapsed 
and refractory multiple MM; however, patients treated with 
IMiDs should be monitored for the risk of infections (500). 
The possibility of cardiovascular and thrombotic complica-
tions should also be considered. However, Bringhen et al (501) 
analyzed 1,146 individual patient data to assess toxic deaths 
during induction treatment with first‑generation novel agents 
THL, LDM and bortezomib, finding a significant reduction in 
toxicity‑related mortality compared with conventional chemo-
therapy. At present, >60 clinical trials into different types of 
tumor or clinical settings are being conducted using these 
compounds (502).
28. Valproic acid (VPA) 
VPA is a drug used as an anticonvulsant, and is also 
utilized in bipolar disorder and the prevention of migraine 
headaches (503). Although the mechanism is not entirely 
understood, it is hypothesized that its anticonvulsant action 
is due to the blockade of voltage‑gated sodium channels and 
augmented levels of γ‑aminobutyric acid (504).
Histone acetylation and deacetylation are processes via 
which the lysine residues at the N‑terminal tail of the histone 
of the nucleosome are acetylated or deacetylated as a critical 
process of gene regulation (505). The reactions are catalyzed 
by the enzymes histone acetyltransferase (HAT) or histone 
deacetylase (HDAC), respectively (506). VPA is an HDAC 
inhibitor, and histone deacetylation is associated with gene 
silencing (507). Deacetylation allows the histones to wrap DNA 
tightly, preventing access to transcription factors, leading to 
transcriptional repression (506,508‑510). The overexpression 
and increased activity of HDACs are characteristic of tumori-
genesis and metastasis, suggesting an important regulatory 
role of histone deacetylation on oncogene expression (511). 
VPA has been shown to have antitumor activity (512).
The nature of the association between HDAC‑mediated 
epigenetic regulation, and autophagy induction or suppres-
sion remains mostly unknown. It was found in lymphoma 
cells that HDAC inhibition by VPA is indispensable for the 
autophagy‑enhancing effects demonstrated when used in 
combination with the mTOR inhibitor temsirolimus (513). 
Also, patients who have AML benefit from the apoptotic 
induction in tumor cells using VPA (514). Additionally, VPA 
suppresses prostatic tumor growth by increasing androgen 
sensitivity and augmenting cellular prostatic acid phospha-
tase via histone acetylation, leading to dephosphorylation of 
ErbB‑2 (515). Moreover, studies showed that VPA induces the 
expression of cyclin D2, a crucial cell cycle regulatory gene 
that is mostly absent in prostate cancer (516). VPA has also 
been tested in head and neck squamous cell carcinoma, where 
it was demonstrated to increase p21, thus affecting cancer cell 
viability, differentiation marker expression and growth (517).
Studies combining VPA with MTF have demonstrated 
their synergistic anticancer effect, likely due to the p53 
signaling pathway, which induces cancer cell apoptosis (518). 
Another synergetic combination of VPA and ellipticine 
(a topoisomerase II inhibitor) induces apoptosis in neuroblas-
toma cells, due to increasing histone H3 and H4 acetylation (519). 
VPA also exhibited its anticancer effects on bladder cancer in 
combination with melatonin, demonstrating a synergetic effect 
by activating apoptotic, necrotic and autophagy‑associated 
genes (520). Another combination study has shown that VPA 
increases thymidine phosphorylase levels in breast cancer 
cells, thus synergizing the effects of capecitabine (521). Effects 
of VPA on pancreatic and colon cancer were associated with 
reduced levels of amyloid precursor protein (APP); lowering 
the levels of APP was associated with the activation of the 
chaperone GRP78 in cancer cells (521). DNA damage and 
apoptosis through ROS production have been proposed as 
additional mechanisms of VPA in pancreatic and cervical 
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cancer (522). Abdelaleem et al (523) summarizes the evidence 
concerning the antitumor effects of VPA on gliomas. At 
present, >14 clinical trials are investigating the effectiveness of 
VPA in a wide variety of malignant tumors, such as pancreatic, 
bladder, cervix, thyroid and prostate cancers (412).
29. Verapamil (VRP)
VRP, an L‑type calcium channel blocker, is used for the treatment 
of high blood pressure, angina and supraventricular tachycardia 
by blocking voltage‑dependent calcium (Cav) channels. There is 
compelling evidence that CaV channels are expressed in various 
cancers at the gene and protein levels (524). Sun et al (525) 
reported that LNCaP prostate cancer cells displayed Ca2+ tran-
sients following stimulation with 5α‑DHT, which were inhibited 
by VRP. VRP has been shown to induce growth inhibition in 
meningioma cell cultures, as well as in a mouse xenograft 
model (526). Additionally, VRP combined with hydroxyurea 
or RU486 increased meningioma growth inhibition in vitro 
by inducing apoptosis and G1 cell cycle arrest, and in vivo by 
affecting microvascular density (527). Hajighasemi et al (528) 
found that VRP downregulated the production of VEGF in 
human peripheral blood mononuclear cells. VRP has exhib-
ited antiproliferative effects on breast cancer cells in a mouse 
model (529). In a prospective study of 99 patients with anthra-
cycline‑resistant metastatic breast carcinoma, VRP showed 
positive survival effects. In advanced NSCLC, VRP improved 
the survival of patients when administered alongside vindesine 
and ifosfamide (530). However, there are controversial results 
concerning the anticancer properties of VRP (531,532).
As mentioned previously, tumor cells develop a form of drug 
resistance known as MDR, which is linked to the expression 
of P‑gp. VRP is also an inhibitor of P‑gp that, when combined 
with chemotherapeutics, can help to induce intracellular drug 
accumulation (533). Another reported mechanism involves 
autophagy. Autophagy is a natural, highly regulated process 
that involves orderly degradation and recycling of cellular 
materials (232). It has been debated as to whether autophagy 
acts as a tumor suppressor or as a factor that helps the survival 
of malignant cells. However, it has been shown that autophagy 
is more likely to act as a tumor suppressor, according to several 
models (534). VRP led to an accumulation of autophagy‑like 
structures (535). VRP stimulates autophagy, involving a switch 
toward aerobic glycolysis and enhanced lactate production (535). 
VRP can reduce intracellular glucose levels with a reduction of 
lactate products (535). These produce two effects in the cancer 
cell; first, depriving the cells of substrates for anaerobic glyco-
sylation, and secondly, producing a reduction of lactate products 
that maintain an acidic pH and facilitate tumor growth (536). 
Other mechanisms also play a role in the antitumor effects of 
VRP, such as reduced angiogenesis (535‑538). Further inves-
tigation is needed. Currently, one clinical trial is open and 
actively recruiting analyzing the effect of brentuximab, dedotin, 
cyclosporine and VRP in patients with relapsed or refractory 
Hodgkin Lymphoma (clinical trial no. NCT03013933).
30. Zidovudine (AZT) 
AZT is an analog of thymidine synthesized in 1964 as a potential 
anticancer agent, but which failed at that time to have positive 
results (539). In 1983, a retrovirus known as HIV was identified 
as the cause of AIDS. AZT proved to be a potent inhibitor of 
retroviruses, and following several studies, was approved for the 
treatment of HIV (540). AZT blocks the replication of HIV‑1 by 
inhibiting reverse transcriptase (RT); AZT is phosphorylated 
intracellularly to AZT‑triphosphate (AZT‑TP) by thymidine 
kinase, and then is integrated into viral DNA, blocking chain 
elongation (541). Telomeres are the extremes of the chromo-
somes; their DNA consists of repetitive sequences, protecting 
the chromosomal ends. In each cell division, every chromosome 
is duplicated, but DNA polymerases cannot copy all bases in the 
3' end after primer removal, which results in the loss of a certain 
number of telomeric sequences in every cycle. Then, telomeres 
shorten progressively; when telomere length is critical, the 
cell enters into senescence and apoptosis (542). In the case of 
germinal or stem cells, they do not have an incomplete replication 
process; to solve this issue, the vast majority of organisms use 
a specific mechanism to maintain telomere length, executed by 
a specialized holoenzyme called telomerase (543). Telomerase 
is also an RT (structurally similar to HIV RT) comprised of a 
main catalytic subunit (hTERT) and an RNA (hTR) that acts as 
a template for the addition of telomeric sequences at the DNA 
3' end. Telomerase is inactive in most somatic cells; however, 
it is active in 85‑90% of human tumors (544). The fact that 
hTERT is a functional catalytic RT led to a study concerning 
the possibility of inhibiting this enzyme in cancer cells using 
viral RT inhibitors such as AZT. It was demonstrated that AZT 
was preferentially incorporated into telomeric DNA rather than 
non‑telomeric DNA and, for the first time, that telomere short-
ening caused by AZT was irreversible (545,546). Numerous 
other studies observed similar results (541,547‑550). Synergistic 
interactions were seen, with AZT promoting the effects of 
cisplatin, paclitaxel and 5‑fluorouracil (551‑553).
In 2001, the effects of chronic in vitro AZT exposure on a 
mouse mammary carcinoma cell line were investigated (554). 
Treatment with AZT for ≥30 passages completely inhibited 
telomerase activity, inducing progressive telomere short-
ening that led to cell senescence and apoptosis. Regarding 
the antitumor mechanism, AZT-TP is also incorporated 
into eukaryotic DNA in place of thymidine, having low 
affinity for DNA polymerases α, β and γ, and high affinity 
for RT (555). Several non‑telomeric telomerase functions 
have been described, such as transcriptional modulation of 
the WNT/β‑catenin signaling pathway and RNA‑dependent 
RNA polymerase activity; it was concluded that the inhibition 
produced by AZT was a mix of effects between canonical and 
non‑canonical functions (556,557). Recently, Song et al (558) 
demonstrated that AZT decreased angiogenesis by reducing 
receptor tyrosine kinase signaling in endothelial cells.
Currently, AZT is employed in the treatment of 
numerous virus-associated human cancers, including 
Epstein‑Barr‑associated lymphoma, AIDS‑related Kaposi 
sarcoma, primary central nervous system lymphoma, Kaposi 
sarcoma‑associated primary effusion lymphoma and adult T cell 
leukemia (559). As of 2019, >20 clinical trials are ongoing studying 
AZT in the treatment of Kaposi's sarcoma, lymphoma, leukemia 
and other tumors in patients with AIDS. AZT has been tested in 
phase I and II clinical trials for other types of tumor, either alone 
or in combination, showing some tumor regression (560‑564). In 
2012, it was demonstrated that AZT was effective against two 
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Table I. Drug repositioning in oncology.
Drug name  Potential anticancer Clinical trial 
(class of drug) Primary use treatment applications identifier Chemical structure
Artesunate Malaria  Kaposi's sarcoma, NSCLC, NCT02633098 
  melanoma, breast, ovarian,
  prostate and renal cancers
Auranofin Rheumatoid arthritis Melanoma, leukemia, NCT01737502 
  gastrointestinal stromal
  tumor, NSCLC
Albendazole (BZM) Helminths infestation CRC, leukemia, liver and NCT02366884 
  ovarian cancers
Flubendazole (BZM) Intestinal parasites Leukemia, melanoma, ‑ 
  myeloma, neuroblastoma,
  breast cancer
Mebendazole (BZM) Helminths infestation GBM, melanoma, glioma, NCT03925662 
  medulloblastoma
Omeprazole (BZM) Gastrointestinal disease CRC, breast and pancreatic NCT02595372 
  cancers
Chloroquine Malaria, lupus, amebiosis, GBM, NSCLC, pancreatic NCT03243461 
 rheumatoid arthritis  and breast cancers
Chlorpromazine Psychosis Glioma, neuroblastoma,  NCT03021486 
  leukemia, lymphoma, CRC,
  breast and liver cancers
Clomipramine Depression and other Glioma, astrocytoma ‑ 
 psychiatric disorders
 
Desmopressin Central diabetes CRC, lung and breast cancers NCT01623206 
 insipidus 
Digoxin Hearth failure and Breast, prostate, and head NCT01763931 
 arrhythmia and neck cancers
Disulfiram Alcohol deterrent GBM, CRC, melanoma, NCT03323346 
  prostate, ovarian, breast,
  pancreatic and liver cancers
Doxycycline Bacterial infestation GBM, melanoma, breast, NCT02775695 
  ovarian, lung, prostate and
  pancreatic cancers
Fenofibrate Hypertriglyceridemia Medulloblastoma, breast and NCT01356290 
 and mixed dyslipidemia lung cancers
Nelfinavir (HPI) AIDS  Myeloma, sarcoma, GBM,  NCT01065844 
  melanoma, head and neck,
  pancreatic, breast, lung, 
  thyroid and prostate cancers
Ritonavir (HPI) AIDS  MM, glioma, breast cancer,  NCT01009437 
  chronic myeloid leukemia
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Table I. Continued.
Drug name  Potential anticancer Clinical trial 
(class of drug) Primary use treatment applications identifier Chemical structure
Itraconazole Antifungal NSCLC, GBM, medulloblastoma, NCT00769600 
  basal cell carcinoma, breast, lung,
  prostate, ovarian and pancreatic
  cancers
Ivermectin Parasitic infestation  TNBC, CRC, lung and ovarian NCT02366884 
  cancers
Leflunomide Rheumatoid arthritis  Myeloma, melanoma, NET, TNBC, NCT03709446 
  neuroblastoma, prostate, bladder
  and breast cancers
Lithium Depression  Osteosarcoma, leukemia, CRC, NCT03153280 Li(OH)
  GBM, prostate, thyroid, lung,
  stomach, esophageal brain, and
  head and neck cancers
Metformin Type 2 diabetes  CRC, NSCLC, breast, bladder, NCT02285855 
  endometrial, lung, prostate and
  pancreatic cancers
Niclosamide Tapeworm infestation  NET, NSCLC, TNBC, acute NCT02807805 
  myeloid leukemia, osteosarcoma,
  adrenocortical carcinoma, glioma,
  ovarian, prostate, lung, and head
  and neck cancers
Nitroxoline Urinary tract infections Non‑muscle invasive bladder CTR20131716 
  cancer
Acetylsalicylic acid Analgesic, antipyretic,  CRC and CRC liver metastases NCT03326791 
(NSAID) platelet aggregation 
 inhibitor
Celecoxib (NSAID) Familial adenomatous CRC, lung, breast, prostate, bladder, NCT02429427 
 polyposis and head and neck cancers
Diclofenac (NSAID) Antipyretic,   Glioma, skin cancer NCT04091022 
 anti‑inflammatory, 
 analgesic
Ibuprofen (NSAID) Antipyretic,   Glioma, neuroblastoma, CRC, NCT02141139 
 anti‑inflammatory,  prostate, bladder, breast, lung and
 analgesic gastric cancers
Ketorolac (NSAID) Antipyretic,  Oral, head and neck, and breast NCT02470299 
 anti‑inflammatory,  cancers
 analgesic
Naproxen (NSAID) Antipyretic,   CRC, basal and squamous cell NCT02052908 
 anti‑inflammatory,  carcinoma
 analgesic
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Table I. Continued.
Drug name  Potential anticancer Clinical trial 
(class of drug) Primary use treatment applications identifier Chemical structure
Piroxicam (NSAID) Antipyretic, anti‑inflammatory,  Skin cancer ‑ 
 analgesic
Sulindac (NSAID) Antipyretic, anti‑inflammatory,  Colorectal neoplasms NCT01349881 
 analgesic
Sildenafil (PDE5I) Erectile dysfunction NSCLC NCT00752115 
Tadalafil (PDE5I) Erectile dysfunction HCC, metastatic pancreatic NCT03785210 
  cancer
Vardenafil (PDE5I) Erectile dysfunction Gliomas and brain metastases NCT02279992 
Pimozide Several mental/mood disorders Breast, lung, prostate, ovarian ‑ 
  and pancreatic cancers, CRC,
  HCC
Propranolol Infantile hemangioma Breast cancer, CRC NCT00888797 
Riluzole Amyotrophic lateral sclerosis Melanoma, breast and prostate NCT02796755 
  cancerc
Statins Cardiovascular diseases HCC, CRC, prostate cancer NCT04026230 
Thalidomide Nausea and vomiting of  Prostate cancer, lymphoma,  NCT00450008 
 pregnancy leukemia, MM
Valproic acid Anticonvulsant, bipolar Lymphoma, myeloid leukemia,  NCT00670046 
 disorder, migraine headaches CRC, glioma, thyroid, cervical,
  bladder, head and neck, prostate
  and pancreatic cancers
Verapamil High blood pressure, angina,  NSCLC, meningioma,  NCT00706810 
 tachycardia breast cancer
Zidovudine AIDS Lymphoma, MM, breast cancer NCT00854581 
One example of a notable clinical trial is provided for each drug. BZM, benzimidazole derivative; HPI, HIV protease inhibitor; NSAID, 
nonsteroidal anti‑inflammatory drug; PDE5I, phospodiesterase‑5 inhibitor; CRC, colorectal carcinoma; HCC, hepatocellular carcinoma; GBM, 
glioblastoma multiforme; MM, multiple myeloma; NET, neuroendocrine tumors; NSCLC, non‑small cell lung cancer; TNBC, triple negative 
breast cancer.
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human MM cell lines in vitro in a dose- and time-dependent 
manner, promoting cell cycle arrest in S phase. AZT is extremely 
promising. However, additional clinical studies are required to 
search for the full potential of AZT in a clinical setting (565).
31. Concluding remarks
Developing more effective cancer treatments requires not 
only the classical design of new molecules, but also intelligent 
searches for new antitumor medications by repurposing old drugs 
already approved for other uses. Such an approach has certain 
advantages; the development of a new drug is costly and timely, 
whereas drugs that are already approved have defined safety and 
pharmacological profiles. A drug with a long clinical history in 
humans has properly defined pharmacokinetic and pharmaco-
dynamics data, including target identification, toxicity profiles, 
recommended dosage schemes and the consistent recognition 
of adverse effects, often meaning that development for an onco-
logical indication can begin at a later stage, such as phase IIA. 
Furthermore, repositioned molecules often are approved quicker 
with reduced cost. However, there are some hurdles in the path, 
mainly the interests of companies and the costly remaining 
phases of the clinical trials prior to final approval. This review 
underlines the most promising drugs for repurposing, which are 
summarized in Table I, and although more research is needed, 
repositioning could pave the way to new, improved and more 
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